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 Pulmonary fibrosis involves the invasion of lung tissue with fibrotic, scar tissue 
and affects roughly five million people total worldwide. Fibrotic development in the lung 
has several causes, including chronic inflammatory diseases, infections, medical 
compounds, and environmental agents. There is no known cure for the disease, but only 
therapies to improve quality of life. Scar tissue formation must be targeted in order to 
begin to provide any type of cure for fibrotic diseases. In this study, asbestos was used 
to induce pulmonary fibrosis in a mouse model and gene expression studies were then 
performed to identify potential candidate genes involved in asbestos response. One 
gene with the potential to regulate the fibrotic response is SPARC (secreted protein 
acidic and rich in cysteine), a matricellular protein involved in tissue repair, extracellular 
matrix (ECM) regulation, cellular proliferation, and cellular adhesion. The goal of this 
project was to determine the role of SPARC in fibrosis development after asbestos 
exposure, specifically targeting how lack of SPARC expression can influence collagen 
production. I hypothesize that SPARC is a necessary component involved in the fibrotic 
response to asbestos through an influence on collagen deposition in the lung. I have 
found that the expression of SPARC is increased in the lungs of C57Bl/6 wild-type mice 
exposed to asbestos. This increase in expression correlates to higher collagen deposition 
in the lung. The absence of SPARC in these treated mice resulted in a reduction of the 
level of collagen deposition back to baseline. To determine the therapeutic potential of 
these findings, SPARC expression was reduced by small interfering RNA (siRNA) in wild-
type mice already suffering from fibrosis. Collagen deposition in the fibrotic mice that 
received the SPARC siRNA vector showed a significant decrease in collagen accumulation 
when compared to those that did not receive the vector. Overall, these results indicate 
that expression of SPARC is a significant step in the development of lung fibrosis 
through the modulation of collagen deposition and therefore, SPARC may be a potential 
therapeutic target. 
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INTRODUCTION 
 
Pulmonary Fibrosis 
 
 Pulmonary fibrosis is the formation of fibrous connective tissue in the lung in 
excess of normal levels. Gradually, the alveoli at the base of the lung become filled with 
fibrotic tissue, a process known as scarring. This process represents the end stages of 
fibrotic lung diseases, a group of disorders that cause progressive lung scarring in 
response to repeated injury to the lining of the alveoli (MFMER, 2008). This scarring 
makes the exchange of oxygen and carbon dioxide during respiration very difficult. Due 
to the progressive nature of the disease, pulmonary fibrosis can eventually result in 
death. Of the roughly five million individuals that currently have pulmonary fibrosis, 
40,000 will die each year from the disease (Pardo, 2005). There are currently no known 
cures for this disease, and the existing treatments often fail to slow its progression 
(MFMER, 2008). 
 The primary symptom of pulmonary fibrosis is dyspnea (shortness of breath), 
which can occur even when undertaking very simple and routine tasks. Individuals 
suffering from the disease may also experience a dry cough, fatigue, muscle aches, and 
an unexplained weight loss. The severity at which these symptoms occur often differs 
between individuals. Some people may become ill very quickly, while others may not 
experience the effects of fibrosis for several years. Because the scarring associated with 
pulmonary fibrosis cannot be reversed and there are currently no treatments that have 
the ability to halt the progression of the disease, current treatments focus mainly on 
improving quality of life and easing the effects of disease symptoms by reducing 
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inflammation (American Thoracic Society, 2000). Treatments include oxygen therapy to 
improve respiration and the use of corticosteroids like prednisone, often in combination 
with other anti-inflammatory agents, to suppress the activity of the immune system. 
About one in three patients respond to therapy, though this response is only temporary 
and is not effective over time (MFMER, 2008). Lung transplantations are also an option 
for young individuals with severe disease, however donor organs are rare.  
 The cause of pulmonary fibrosis is not always known. Disease development in 
individuals with no identifiable cause is known as idiopathic pulmonary fibrosis. There 
are, however, several known causes of pulmonary fibrosis, including exposure to 
asbestos (asbestosis), silica (silicosis), cigarette smoke, hard metal dust, or 
chemotherapy drugs, that can manifest in the scarring mentioned above (American 
Thoracic Society, 2000). Once the small air sacs at the bases of the bronchioles are 
irreversibly damaged through the build up of scar tissue, the lung no longer has the 
same elasticity thereby hindering respiration. Gradually the alveolar architecture is 
destroyed and the scarring results in air-filled cystic spaces giving the appearance of a 
honeycomb lung (West, 2007). Basically, instead of being soft and flexible, the alveoli 
become very stiff and thick like a dry sponge. This hinders the ability of the lung to 
transfer oxygen into the blood and remove carbon dioxide.  
 The pathology leading to the development of pulmonary fibrosis involves the 
complex interaction between several factors including epithelial cells, interstitial cells, 
inflammatory cells, cytokines, fibroblasts and the extracellular matrix (Bienkowski, 
1995). After exposure to an insult like silica or asbestos, blood leukocytes and 
fibroblasts, which are widely distributed in lung structures, are recruited to the site of 
injury (Savani, 2000; Laurent, 2007). This mobilization is due to stimulation from 
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cytokines and growth factors like TGF-β, PDGF, and IL-1 (reviewed in Laurent, 2007). 
TGF-β, in particular, may be one of the central players involved in the development of 
remodeling diseases like pulmonary fibrosis (Coker, 1997). Once recruited to the area, 
fibroblasts begin to lay down collagen fibers and further stimulate the immune system 
through the recruitment and activation of macrophages. As the macrophages die over 
time, they release cytokines that recruit new macrophages and more fibroblasts. This 
constant activation of fibroblasts leads to continuous collagen accumulation in the lung 
and scar tissue formation. A simplified version of this cyclic pathology is depicted in 
Figure 1.  
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 Figure 1: The Process of Scar Tissue Formation in Pulmonary Fibrosis  
 
 
 
 
 
 5 
Figure 1 Legend: The cellular process leading to the development of pulmonary fibrosis 
is a cycle involving the continuous recruitment of macrophages and other immune cells, 
activation of fibroblasts, and constant collagen deposition leading to the formation of 
scar tissue at the lung bases. Insult images from: 
http://farm4.static.flickr.com/3218/2849103016_ef7933bdcd.jpg (hard metal 
dust),  
http://www.bedfordlabs.com/products/images/bleo.jpg (bleomycin), 
http://msmc.gov.in/minerals/SilicaSand.jpg (silica) 
http://www.umt.edu/libbyhealth/gifs/secondary/science/crocidolite.gif (asbestos) 
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Asbestosis 
 
 Asbestosis is defined as interstitial fibrosis, or pneumoconiosis, induced by the 
inhalation of asbestos fibers (American Thoracic Society, 2004). It is a progressive, long-
term disease of the lung that will present with signs of decreased diffusion capacity, 
total lung capacity, and vital capacity (O’Reilly, 2007). The actual number of individuals 
suffering from asbestosis in the United States is unknown, however there were 
approximately 20,000 diagnoses in the year 2000 with 2,000 deaths where asbestosis 
was reported as the cause (U.S. Department of Health and Human Services, 2003; 
Centers for Disease Control and Prevention, 2004). The number of individuals that suffer 
from asbestosis is expected to rise within the next decade due to the long latency period 
associated with disease development. It is expected that a peak in disease will follow 30 
to 40 years after the peak in mining/production, which occurred in the 1960s and 1970s. 
Therefore many more people will continue to develop asbestosis so we must strive to do 
what we can to find a cure in the near future. 
The symptoms associated with asbestosis are typical of pulmonary fibrosis, with 
the primary symptoms including shortness of breath, chest pain, and a dry cough. 
Individuals suffering from asbestosis also have a higher risk of developing lung cancer 
(Van Loon, 1997) and this risk is magnified several-fold by smoking (Boffetta, 2004; 
Liddell, 2001; Berry, 2004). The disease appears to be most severe at the base of the 
lungs where the asbestos fibers deposit after inspiration. In the alveoli, fibroblasts are 
stimulated to lay down collagen to wall off the fibers and macrophages are recruited and 
activated to destroy them. Unfortunately, due to the natural resistance of asbestos to 
phagocytosis, this process becomes repetitive leading to the development of scar tissue 
as was previously described (Figure 1). Because the pathology of asbestosis is 
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congruent with typical lung fibrotic disease, it is a good model for further study into the 
development of pulmonary fibrosis in the hopes of developing an effective treatment or 
even a cure.  
 
Asbestos 
 
 Asbestos is a naturally occurring mineral composed of long, thin fibrous crystals. 
The fibers have been used for over 2,000 years and were particularly popular in the 
building industry due to their high tensile strength, sound absorption, and resistance to 
heat, electricity, and chemical damage. These properties made asbestos ideal for use in 
products that required flame-retardation, flexibility, chemical resistance, and strength, 
which included insulation, house siding, electrical wiring, and brake pads among others.  
There are two forms of asbestos, the needle-like amphibole fibers and the curly 
serpentine fibers. All forms of asbestos are fibrillar in nature in that they are made up of 
fibers with widths less than one micrometer. These fibers occur in bundles and can have 
long lengths. Chrysotile, which composes the serpentine group, is the most common 
form of asbestos used in industry and accounts for approximately 95% of the asbestos 
found in buildings in the United States (Wisconsin Department of Natural Resources, 
2007). It is typically used in brake linings, pipe insulation, floor tiles, and cement roof 
sheets. The use of chrysotile asbestos has been banned in many countries, however it is 
allowed in the United States and Europe with limitations. 
There are several members of the amphibole asbestos group including amosite, 
crocidolite, tremolite, actinolite, and anthophyllite (American Cancer Society, 2006). 
These fiber types are commonly used as fire retardant in thermal insulation products 
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and ceiling tiles. Like chrysotile, asbestiform amphibole can be found as soft friable 
fibers, but varieties such as amosite are much straighter. Amosite, or brown asbestos, is 
the second most common form of asbestos found in buildings (U.S. EPA, 2008). 
The use of asbestos became very popular during the industrial revolution where 
it was utilized as insulation in the United States and Canada. Beginning in World War II, 
asbestos was also extensively used in the ship industries. By the middle of the 20th 
century, the use of asbestos had expanded to include materials composing lawn 
furniture, drywall, and concrete. This increase in the use and production of asbestos led 
to the discovery of its toxicity. During the early 1900’s, researchers began to notice a 
higher incidence of lung disease and death in asbestos mining towns. By the 1930’s 
England identified asbestos-induced lung fibrosis, or asbestosis, as a work-related 
disease, an insight that was not recognized by the United States for another ten years 
(American Cancer Society, 2006; Asbestos Resource Center, 2008). The United States 
government has been criticized for not acting quickly enough to prevent asbestos 
exposures after the toxicity of the fibers was recognized. 
Since the mid 1980’s, the use of asbestos in many countries has been banned 
due to its toxicity. However, exposures are still occurring. In 2006, 2.3 million tons of 
asbestos were still processed worldwide, mainly in Russia, China, Kazakhstan, and 
Canada (Hetherington, 2008) (Figure 2). The United States last mined asbestos in 2002 
but exposures still arise because many homes still contain asbestos in their 
insulation/siding. In addition, the United States still uses asbestos in the production of 
new materials under limited conditions (EPA Asbestos Materials Bans, 1999).  
 9 
 Figure 2: Worldwide Production of Asbestos 
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Figure 2 Legend: Many countries still produce asbestos today. In 2006 a total of 2.3 
million tons of asbestos were produced worldwide with the major producers being 
Russia, China, and Kazakhstan. Data obtained from World Mineral Production 2002 – 
2006, British Geological Survey (Hetherington, 2008). 
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The inhalation of airborne asbestos fibers can cause a variety of respiratory 
illnesses including asbestosis, lung cancer, and malignant mesothelioma. It is estimated 
that approximately 10,000 people die from an asbestos-related disease each year, and 
this number is expected to rise (Environmental Working Group, 2004). This rise is based 
on the knowledge that asbestos related diseases have approximately a 40 year latency 
period, which means that individuals who previously worked in the asbestos mines and 
factories may just now be showing signs of disease. Because there appears to be no end 
in sight for mining/use of asbestos or the destruction of all of its existing products, 
people will continue to be exposed to asbestos. Therefore, a thorough understanding of 
asbestos-related diseases is necessary to help those individuals.  
For the purpose of this project, I focused on the development of asbestos-
induced fibrosis (asbestosis) after exposure to one of two forms of asbestos: the 
amphibole found as a contaminant in the vermiculite mines in Libby, Montana (Libby 
amphibole) and the well-studied crocidolite amphibole fibers. 
 
Libby Amphibole 
  
The small town of Libby is located in the northwestern corner of Montana, 
approximately 30 miles south of the Canadian border. The economy of Libby has 
primarily been supported by the utilization of natural resources through mining and 
logging. Prior to 1990 the main sources of employment were the logging industry and 
vermiculite mining. Vermiculite ore was found in the area in 1881 and was mined from 
1919 to 1990 (U.S. EPA Region 8, 2008). Vermiculite is typically defined as a hydrated 
laminar magnesium-aluminum-iron silicate resembling mica in appearance (U.S. EPA, 
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2008). The vermiculite was used in the production of Zonolite, the trademarked product 
made from vermiculite. In 1953 the vermiculite was found to be contaminated with 
asbestiform fibers, though, the fibers were not extensively studied until the late 1970’s 
(McDonald, 2004). This contamination could explain the high number of asbestos-
related diseases affecting Libby residents (Zalac, 2003). 
W. R. Grace and Company bought the vermiculite mine in 1963 and continued to 
operate it until 1990 even though it had been known since 1956 that the vermiculite was 
contaminated with asbestos. Unfortunately, exposure to the vermiculite was not isolated 
to the Libby community as the vermiculite was shipped for use as insulation in homes all 
over the United States. In fact, it is estimated that 35 million homes in the United States 
still contain the Zonolite insulation (U.S. EPA, 2008). Today, the town of Libby is an EPA 
superfund site and has been the subject of 120 million dollars in cleanup efforts (Office 
of Inspector General Report, 2007). 
The asbestos found in Libby vermiculite is a combination of amphibole fibers and 
cleavage fragments that include tremolite, actinolite, soda tremolite, richterite, and 
winchite (Meeker, 2001). These fibers can form blocky crystals, non-flexible cleavage 
fragments, or long flexible fiber bundles (Meeker, 2003). They also differ in their length 
and in the cations expressed on their surface, where the various fibers that compose 
Libby asbestos all have different proportions of cations like Mg2+, Ca2+, Fe2+, Na2+, and 
K+ (Webber, 2008). Based on the varied composition of Libby amphibole, the fibers are 
very different from other amphiboles and may therefore induce different effects in 
exposed tissues. 
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Crocidolite 
  
Crocidolite, or blue asbestos, is mainly found in Africa but deposits also occur in 
Australia. It is the asbestiform of the mineral riebeckite. Crocidolite asbestos accounts 
for roughly 4% of the total asbestos used in the United States and is considered by 
some to be the most hazardous of the amphibole group (Mesothelioma & Asbestos 
Wellness Center, 2008). Because it is much less resistant to heat than other forms of 
asbestos, crocidolite was most often utilized in asbestos-cement products. Due to its 
hazardous nature, crocidolite asbestos provides a good fiber type for the further study of 
asbestos-induced pulmonary fibrosis. 
 
SPARC 
 
 A protein that may be involved the lung’s fibrotic response to an insult like 
asbestos through the mediation of cell-matrix interactions is Secreted Protein Acidic and 
Rich in Cysteine (SPARC), also known as osteonectin or BM-40 (Lane, 1994; Reed, 
1996). SPARC is a 43kD protein that belongs to a group of structurally distinct proteins 
with similar functions that include thrombospondin, tenascin, and Hevin. These 
matricellular proteins can interact with cell-surface receptors, the extracellular matrix, 
growth factors and proteases while not contributing directly to the structural properties 
of the extracellular matrix (Bornstein, 2002). They are activated during tissue renewal, 
tissue remodeling, tissue repair, and embryonic development (Bornstein, 1995; Sage, 
1989), and since its discovery, SPARC has been shown to function as a modulator of 
growth factor activity (Raines, 1992; Kupprion, 1998; Murphy-Ullrich, 1991; Schiemann, 
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2003), a counteradhesive protein (Murphy-Ullrich, 1991; Rosenblatt, 1997), a modulator 
of cell proliferation (Funk, 1991; Kupprion, 1998) and migration (Hasselaar, 1992; Wu, 
2006), a regulator of the extracellular matrix (Tremble, 1993; Barker, 2005), and a cell 
cycle inhibitor (Funk, 1991). 
 SPARC expression is widespread during early development, but in the adult 
expression is mainly localized to tissues undergoing repair or remodeling, such as the 
bone and lining of the gut (Sage, 1989). These processes can be the result of wound 
healing, disease, or natural processes. Expression of SPARC is localized to several cell 
types including steroidogenic cells, chrondrocytes, placental trophoblasts, vascular 
smooth muscle cells, and endothelial cells (Porter, 1995). In injured tissues it is highly 
expressed in fibroblasts, epithelial cells, and macrophages (Porter, 1995; Puolakkainen, 
1999; Reed, 1993; Latvala, 1996). As these are some of the primary cell types involved 
in pulmonary fibrosis, SPARC may play a significant role in the development of the 
disease, and has already been shown to accumulate in the fibrotic lung (Kuhn, 1995; 
Strandjord, 1999). 
 Protein crystallization has allowed for the identification of three structural 
modules in SPARC that include an acidic domain, a follistatin-like domain, and an 
extracellular calcium binding domain (Figure 3). The acidic domain or NH2-terminal 
domain (amino acids 1-52) is involved in the inhibition of cell spreading 
(Hasselaar,1992), causes cell rounding and de-adhesion (Lane, 1990) and can influence 
the expression of extracellular matrix protein (Lane, 1992). The follistatin-like domain 
(amino acids 52-137) has been shown to inhibit cell proliferation (Funk, 1993), delay the 
cell cycle (Funk, 1991; Funk, 1993), and be involved in SPARC’s recruitment to its cell 
surface receptors (Hohenester, 1997). The extracellular calcium-binding domain (amino 
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acids 138-286) has also been shown to inhibit cell spreading and proliferation (Kupprion, 
1998; Motamed, 1998). Furthermore, this third domain is known to stabilize the binding 
of Ca2+ to the protein (Hohenester, 1997), which then allows the binding of collagen 
types I, III, and V to this extracellular module in a calcium dependent manner (Sasaki, 
1997). As most of the functions of SPARC are calcium dependent, this third domain is 
primarily responsible for SPARC’s involvement as a tumor suppressor and in cell-matrix 
interactions. 
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 Figure 3: SPARC Structure 
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Figure 3 Legend: SPARC has three structural domains: an acidic domain (black), 
follistatin-like domain (red, green, black), and an extracellular calcium-binding domain 
(blue, yellow). Adapted from Hohenester et al. (1997), Brekken et al. (2001), and the 
RCSB Protein Data Bank, formerly the Brookhaven Protein database, accession number 
1BMO. 
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A mediator of SPARC expression is the cytokine transforming growth factor β 
(TGF-β). TGF-β is a multifunctional growth factor involved in growth, differentiation, 
proliferation, tissue remodeling, and wound healing (Pepper, 1997). It is also 
responsible for the stimulation of fibroblasts to both proliferate and increase the 
synthesis of extracellular matrix components (Border, 1994). In addition, it has recently 
been found that exogenous TGF-β1 induces an increase in both SPARC and collagen 
type I expression (Reed, 1994).  
SPARC is capable of stimulating the TGF-β pathway through interactions with the 
TGF-β receptor complex only if TGF-β is already bound to the receptor (Franki, 2004). If 
TGF-β1 is bound to the TGF-β type II receptors it can recruit and phosphorylate TGF-β 
type I receptors and initiate a signal cascade (Heldin, 1997). It had been suggested that 
if SPARC is also bound to this receptor complex, it could dictate which of the TGF-β 
signaling pathways is activated, and it was later discovered that it does. Though more 
research is needed on the precise mechanism by which SPARC triggers TGF-β signaling 
events, there are several possibilities for which specific cascades are activated in 
SPARC’s presence. These include the activation of either JNK or SMAD2/3 pathways, 
both of which result in an increased synthesis of collagen (Franki, 2004). Figure 4 
depicts these pathways. Aside from interacting directly with extracellular membrane 
components like collagen, it is now known that SPARC can increase the transcription of 
collagen as well. 
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 Figure 4: SPARC’s Involvement in the Pathway Leading to the Synthesis of 
Collagen 
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Figure 4 Legend: In a ligand-dependent manner, SPARC can bind the TGF-β receptor 
complex and initiate the activation of either the JNK (red arrows) or SMAD2/3 (blue 
arrows) signaling cascades to stimulate the transcription of collagen mRNA. This model 
is based on one published by Francki et al. in 2004. 
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 To better understand the relationship between SPARC and collagen, SPARC-null 
(SP-null) mice were created.  Previous investigations have used the SP-null mice in 
conjunction with bleomycin treatment to elucidate the influence of SPARC on collagen 
accumulation in a fibrotic lung. Bleomycin is a chemotherapeutic agent whose 
administration is known to cause lung fibrosis in several species of animals (Schrier, 
1983; Snider, 1978; Starcher, 1978; Swiderski, 1998) that undergo a sequence of 
inflammatory cell migration, edema, cell proliferation, and collagen accumulation 
characteristic of fibrotic disease in humans (Brown, 1988; Lazenby, 1990). Results of 
these investigations have been conflicting, though the conditions under which they were 
performed were somewhat different. The first study was performed in a C57Bl/6-129 
cross mouse using a low dose of bleomycin to induce fibrosis through a transtracheal 
puncture. It was discovered in this study that lack of SPARC significantly decreased total 
collagen accumulation in the lung (Strandjord, 1999). The second study used 129 mice 
and a high dose of bleomycin injected intratracheally to show that lack of SPARC leads 
to an increase in collagen accumulation in the fibrotic lung (Savani, 2000). Regardless of 
the opposing outcomes, it is apparent from these studies that SPARC does play a role in 
the amount of collagen deposited in the fibrotic lung and therefore may be interesting to 
study in terms of asbestosis. 
 In order to determine if SPARC is a potential candidate for further study in a 
model of fibrosis induced by asbestos, a long-term exposure (1 year & 6 months) study 
was performed. 
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Long-Term Asbestos Exposure Study 
 
A version of this study has been published: Putnam EA, Smartt A, Groves A, Schwanke 
C, Brezinski M, Pershouse MA. Gene expression changes after exposure to six-mix in a 
mouse model. J. Immunotoxicol. 5: 139-144. 2008. 
 
Abstract 
 
 The exposure of Libby MT residents to amphibole-contaminated vermiculite has 
been well documented in the literature (Amandus, 1987; McDonald 1986, 2004; 
Sullivan, 2007). To explore the gene-environment interactions in the development of 
asbestos-related diseases (ARD), a mouse model of asbestos exposure using Libby 
amphibole (a combination of amphibole fibers gathered from six sites at the Libby 
vermiculite mine), crocidolite asbestos, or phosphate buffered saline as a negative 
control was used to both determine gene expression responses by using mouse 10,000 
oligonucleotide array and to visualize histological changes.  One year and six months 
following exposure via intratracheal instillation, mice were sacrificed and whole lungs 
harvested for histology and microarray analysis. Using an arbitrary cutoff of 1.25 fold 
change, genes whose RNA expression levels were specifically altered in response to the 
different amphibole exposures were grouped into categories by a gene ontology analysis 
program, GoMiner. Our hypothesis was that assessment of asbestos-responsive genes 
would provide a better understanding of response mechanisms. These experiments have 
provided new candidate genes that may be involved in the asbestos response pathways. 
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Introduction 
 
A serious public health situation has been identified in Libby, Montana where 
miners and town residents were exposed to hazardous levels of asbestos from the local 
mining operation. Vermiculite was mined, transported, and processed in the area from 
1923 to 1990. Most vermiculite ore is not a health hazard and is used in many consumer 
products including insulation, fireproofing material, and lawn/garden products. However, 
the Libby ore is different in that it is contaminated 21-26% with asbestos by weight 
(Atkinson, 1982). As a result of the asbestos contamination, Libby has been designated 
as an Environmental Protection Agency (EPA) Superfund site.  
Prolonged exposures to asbestos can manifest in a variety of health problems 
including asbestosis, lung cancer, and mesothelioma. In December 2000 the Agency for 
Toxic Substances and Disease Registry (ATSDR) conducted a mortality study on the 
Libby population for a twenty-year period encompassing 1979 – 1998. It was reported 
that there was a 20% to 40% increase in malignant and nonmalignant respiratory 
deaths. In particular mesothelioma mortality was elevated, asbestosis mortality was 40 
to 80 times higher than expected, and lung cancer mortality was 1.2 to 1.3 times higher 
than expected when compared to the rest of the United States (ATSDR, 2000).  
 Previous studies in mice have shown that after asbestos exposure, a complex 
network of cytokines, growth factors, and receptors are involved in initial inflammation 
and ensuing asbestosis and carcinogenesis (Geist, 2000; Shukla, 2003). We have used 
gene expression studies in a mouse model to identify potential candidate genes involved 
in asbestos response. In addition, exposed lungs were visualized for histological changes 
consistent with fibrosis. Thus, the goal of this study was to identify the fibrotic effects of 
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crocidolite asbestos and the amphibole fibers from the Libby, Montana vermiculite mine 
and to indicate specific pathways of response to these fibers for future studies. 
 
Materials and Methods 
 
Amphiboles: Libby amphibole comprised of samples 20, 23, 25, 27, 28 and 30 from the 
vermiculite mine in Libby, MT as described (Meeker et al., 2003) were generously 
provided by the U.S. Geological Survey. This amphibole has been characterized in detail 
(Wylie, 2000; Gunter, 2003; Meeker, 2003) and the Libby amphibole samples used also 
have a particle size distribution matching air sample size distribution data (Meeker, 
2003). Crocidolite asbestos was obtained from the Research Triangle Institute (Research 
Triangle Park, NC). The fiber size distribution of both Libby amphibole and crocidolite 
asbestos has been previously reported (Blake, 2007). For reference, size parameters of 
the Libby amphibole sample were 0.61 µm in diameter, 7.21 µm in length, with 22.52 
for the aspect ratio. Size parameters of the crocidolite were 0.16 µm in diameter and 
4.59 µm in length, with a 34.05 aspect ratio. Samples were freshly prepared in sterile 
phosphate-buffered saline (PBS, pH 7.4) and sonicated before instillation. 
 
Mouse Treatment: C57Bl/6 mice six to eight weeks of age were divided into three 
groups of at least seven mice each and treated via intratracheal instillation with 100µg 
of Libby amphibole or crocidolite asbestos in 30 µL of sterile phosphate buffered saline 
(PBS).  PBS alone was instilled in vehicle control mice.  The mice were sacrificed and the 
lungs harvested for study one year or six months after instillation. 
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RNA Isolation: Treated mouse lungs were homogenized in the presence of TRIzol 
reagent and RNA was isolated following the manufacturer’s protocol (Invitrogen, 
Carlsbad, CA). Additional purification of the total RNA was performed using an RNeasy 
kit (Qiagen, Valencia, CA). 
 
Microarray Analysis:  RNA was analyzed by microarray hybridization to a 10K element 
mouse oligonucleotide array based on set A from MWG-Biotech (High Point, NC). Gene 
expression was analyzed relative to mouse reference standard RNA (Stratagene, La 
Jolla, CA), enabling experiment-to-experiment comparison. Alterations of transcript 
levels were characterized by fold-change, k-means cluster analysis, and principle 
components analysis.   Genes with expression changes were organized into biologically 
relevant categories and assessed for significance using the GoMiner program 
(http://discover.nci.nih.gov/gominer/).  Assays and analyses were performed in the 
Microarray core at The University of Montana Center for Environmental Health Sciences. 
 
Histology: Mouse lung samples were perfused and immersed in Histochoice fixative 
(Amresco, Solon, OH), embedded in paraffin, and sliced into 7µm sections for analysis. 
Routine Gomori’s trichrome staining was performed in the Molecular Histology & 
Fluorescence Imaging Core and the sections examined under light microscopy.   
 
Lucifer yellow (LY) staining:  LY has been shown to bind to collagen, enabling 
quantification of the extent of fibrosis based on the amount of collagen present 
(Antonini, 2000; Taylor, 2002.  Briefly, histologic tissue sections were incubated in 
Lucifer Yellow-CH (1 mg/mL) (Molecular Probes, Eugene, OR) for one hour at room 
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temperature, washed in dI water and cover-slipped with water soluble, anti-fade 
mounting medium (Immuno Concepts, Sacramento, CA). LY-stained tissue was 
quantitated using a Laser Scanning Confocal Microscope (LSC), (CompuCyte, Cambridge, 
MA) in the Fluorescence Cytometry Core fitted with an argon-ion laser. Wincyte software 
(CompuCyte Corporation) was used in the analysis.  
 
Statistics:  Mean values obtained from quantitation of the LY-stained sections of 
amphibole and PBS-exposed mouse lungs were compared using One-Way ANOVA with a 
Newman-Keuls Multiple Comparison Test. 
 
Results 
 
Six months after instillation, lungs from animals exposed to Libby amphibole (LA) 
and crocidolite asbestos (CRO) demonstrated fibrosis development with increased 
cellularity (inflammation) and elaboration of extracellular matrix (collagen appears blue-
green in Gomori Trichrome-stained sections, Figure 5B and 5C).  Arrows indicate areas 
of increased collagen deposition. Although fibrotic areas were identified in the LA treated 
mouse lung sections, the level of collagen deposition around the airways appeared to be 
less than that seen in crocidolite asbestos treated lung sections included as positive 
control. No fibrotic areas were identified in sections from mouse lungs instilled with PBS 
as the vehicle control (Figure 5A).  
At one year post instillation, collagen is no longer deposited in increased 
amounts in the amphibole treatment groups as is seen at six months post-exposure 
(Figure 5E and 5F). There still appears to be a significant increase in inflammation made 
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apparent by the increased cellularity and appearance of macrophages (large red cells). 
Again, the PBS control animals show no signs of inflammation or increased collagen 
deposition (Figure 5D). Due to the lack of collagen deposition around the airways, it 
appears as though the fibrotic disease process is resolving from six months to one year. 
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Figure 5: Mouse Lung Sections Exposed for 1 Year or 6 Months to Crocidolite 
Asbestos (CRO), Libby Amphibole (LA), or a PBS Control. 
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Figure 5 Legend: Gomori Trichrome-stained 7µM sections of mouse lungs from animals 
instilled with crocidolite asbestos (CRO), Libby amphibole (LA), or sterile saline (PBS) as 
a vehicle control for comparison (200X original magnification).  Blue-green staining 
indicates collagen deposition and arrows point to areas of increased accumulation.   
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To quantify mouse lung collagen deposition, an assay using lucifer yellow to stain 
for collagen was performed.  This assay allows for collagen quantitation without the 
tissue destruction required by a hydroxyproline assay. Figure 6 demonstrates the mean 
fluorescence intensities seen in histology sections of mouse lungs.  While mean 
fluorescence intensity was increased in lungs from both treatment groups, lungs from 
the crocidolite-treated mice demonstrated a statistically significant increase over PBS-
treated control mice (n = four in each group). Collagen levels in LA instilled mice, while 
elevated, did not rise to statistical significance when compared to control animals.  This 
lack of significance could be due to the limited number of mice used in the assay or the 
exposure time. As there appeared to be no difference in collagen accumulation one year 
after treatment, the lucifer yellow assay was not performed. 
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Figure 6: Quantitation of Lucifer Yellow Stained Lung Tissue 6 Months Post 
Exposure. 
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Figure 6 Legend: Quantitation of Lucifer Yellow stained tissue.  Stained tissue was 
scanned using a Laser Scanning Confocal Microscope fitted with an argon-ion laser.  A 
circular area having a radius of 700 microns was scanned at approximately the same 
location on each section using a series of smaller scan areas called phantoms, each 
having a radius of 8mm.  The mean fluorescent intensity for the phantoms in each scan 
area was recorded and analyzed using Wincyte software.  The phantoms that were 
saturated or below a set threshold were gated out and were not included in the analysis.  
This eliminated background areas and artifacts from the analysis.  Intensity values were 
obtained from every tenth section (for a total of 15 sections) for each lung and added 
together for each animal. Angie Groves performed this assay while working as an 
undergraduate in our lab. I completed the statistical analysis using one-way ANOVA with 
a Newman-Keuls Multiple Comparison test.  (* = p < 0.05) 
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Gene expression analysis was performed on pooled aliquots of RNA from seven 
to eight animals per exposure and the results analyzed with the GoMiner program from 
NCBI.  Results from LA and CRO exposed animals demonstrated gene expression 
changes in multiple pathways at both time points (Figure 7, Table 1). Similar responses 
were seen at both one year and six months with the highest number of expression 
changes occurring in the regulation of cell proliferation functional group.  Numerous 
changes were also seen in the extracellular matrix and the regulation of signal 
transduction functional groups. Expression changes were also seen in groups with genes 
involved in apoptosis, fibrosis, tumor formation, and oxidative stress. Overall, it is also 
apparent that expression changes are not as frequent at one year as six months, again 
indicating that the disease process in mice may be resolving from six months to one 
year. 
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Figure 7: GoMiner analysis of RNA expression changes determined by 
microarray analysis both 1 Year and 6 Months post exposure. 
 
 
A. 
B. 
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Figure 7 Legend: GoMiner analysis of RNA expression changes determined by microarray 
analysis. Genes exhibiting at least 1.25 fold up- or down-regulation in treated lungs 
compared to controls were grouped with GoMiner (NCBI) into functional categories. The 
functional groups are graphed to include the total number of genes with changed 
expression. 
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Table 1: Number of Gene Alterations After Long-term Exposure to Asbestos 
* LA altered genes / [CRO altered genes] 
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Discussion 
 
Despite intensive investigation, the mechanisms of asbestos toxicity have yet to 
be delineated.  The development of lung disease has been related to both the 
cumulative dose and the time since first exposure, with asbestos-related diseases (ARD) 
typically arising after a 15-40 year latent period.  Recent reviews have detailed evidence 
of various pathogenic pathways of asbestos-induced lung diseases, which include: 1) the 
chemical and structural properties of the fibers, 2) the lung fiber burden, 3) fiber uptake 
by lung epithelial cells, 4) iron-catalyzed free radicals, 5) DNA damage, 6) 
cytokines/growth factors, and 7) exposure to cigarette smoke and other pulmonary 
toxicants (reviewed in Kamp 1999, Manning 2002).  No single mechanism has been 
found to explain the abnormalities caused by asbestos, and the exact pathogenic 
pathways and their regulation have not been determined. Through the analysis of gene 
expression changes found in mouse lungs after asbestos exposure, our studies will aid in 
determining the contribution of these various mechanisms on the initiation and 
progression of asbestos-related diseases. 
The physiological effects of crocidolite asbestos have been well studied for many 
years, but the effects of the Libby amphibole (LA) are still under investigation.  The 
asbestos-related diseases seen in the exposed Libby population make it essential to 
determine the mechanism of action of this material, and to compare the effects of the 
LA to the effects of other, well-characterized amphiboles.  Using crocidolite asbestos as 
a well-characterized fiber for comparison (Hamilton, 2004; Wang, 2006; Baldys, 2007), 
we studied the effects of the LA in a mouse model of exposure. LA and crocidolite both 
produced increased collagen deposition in a mouse model of asbestosis, as 
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demonstrated by both Trichrome staining and lucifer yellow quantitation.  In both 
exposures, the extent of fibrosis in terms of collagen deposition was consistently 
reduced in LA exposed mouse lungs compared to lungs exposed to crocidolite asbestos.  
This could have been due to some of the differences between LA and CRO including 
fiber length, diameter, and surface charge. For example, crocidolite is smaller in both 
length and diameter than LA. 
Gene expression changes after asbestos exposure have been studied in vitro 
(Nymark, 2007). The analysis of changes in gene expression in whole lung tissue after 
exposure to asbestos may provide new directions for research into the mechanisms of 
fibrosis development.  Our results demonstrate that after a long-term exposure (1 year, 
6 months) to either LA or crocidolite, there are both similarities and differences in the 
gene expression changes seen as analyzed with the gene ontology analysis program 
from NCBI, GoMiner.  This program assigns genes to functional categories and assesses 
the significance of the expression level differences from control (PBS) before the 
expression of a particular gene is included as “altered” in the category.  As expected 
after exposure to fibers that cause fibrosis, the greatest number of expression changes 
were seen in the regulation of cell proliferation functional category after both LA and 
crocidolite exposure.  Similarly, the functional categories of extracellular matrix genes 
and regulation of signal transduction genes also had numerous changes in expression 
levels.  At six months, the number of altered genes was greater after crocidolite 
exposure compared to LA exposure in every category found to be significant except for 
the expression of genes involved in DNA repair. This effect is the opposite for the major 
categories of alteration at one year, with mice exposed to LA having more genetic 
alterations than CRO exposed mice. This may indicate that fibrotic disease in mice 
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exposed to CRO may resolve faster than in mice exposed to LA. As the disease process 
does not resolve in humans, it will be important to assess fibrotic and gene expression 
changes at earlier times after exposure in order to better understand the mechanisms 
underlying fibrotic disease development as it relates to humans. 
 
Conclusions 
 
 Both Libby amphibole and crocidolite asbestos induce gene expression changes 
in mice exposed long term. However, these changes are not as numerous at one year as 
they are at six months indicating that in order to use mice as a model of the fibrosis 
seen in humans, earlier exposure time points must be used. Also it is apparent that 
though LA induces fibrosis like crocidolite, it may do so in a different way as the gene 
alterations between the two groups differ. Further study is needed to determine the 
influence these differences have on fibrosis development, and to potentially identify 
candidate genes that may play a significant role in the disease process. 
 
This project was supported by CCR822092 (CDC) and RR017670 (NCRR).  
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CHAPTER ONE 
Collagen Accumulation After Short-Term Exposure to Crocidolite Asbestos or Libby 
Amphibole 
 
This study is in press: Smartt AM, Brezinski M, Trapkus M, Gardner D, Putnam EA. 
Collagen accumulation over time in the murine lung after exposure to crocidolite 
asbestos or Libby amphibole. Environmental Toxicology. 2009. 
 
Abstract 
 
Libby, MT is the site of a closed vermiculite mine that produced ore 
contaminated with asbestos-like amphiboles. Worldwide distribution of the material and 
the long latency period for manifestation of asbestos-related diseases (ARDs) has 
created a significant health threat for many years to come. The composition of the Libby 
material (termed the Libby amphibole, LA) differs from other well-studied types of 
asbestos in that it is a mixture of several amphibole fibers. The purpose of this study 
was to determine the fibrotic effects of LA exposure in a mouse model and to compare 
these effects to those of a well-characterized amphibole fiber, crocidolite asbestos. We 
exposed C57Bl/6 mice to LA or crocidolite and analyzed lung RNA, protein, and 
morphology at one week, one month, and three months post instillation. Our results 
indicate that both forms of amphibole studied induced increased collagen types I and III 
mRNA expression and collagen protein deposition in exposed murine lungs compared to 
the PBS-instilled control lungs. These collagen increases were the most significant at one 
month after exposure. Overall, crocidolite exposed mice demonstrated greater increases 
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in collagen deposition than those exposed to LA, indicating that the fibrotic effects of LA 
exposure, although not as severe as those of crocidolite in this model system, were still 
able to induce collagen deposition. 
 
Introduction 
 
Vermiculite ore, a hydrated laminar magnesium-aluminum-iron silicate, expands 
to between 10 and 20 times its original size when heated and has several useful 
commercial applications including those in construction, industrial, and agricultural 
products (U.S. EPA, 2008; Moatamed, 1986). Libby, Montana was the site of a 
vermiculite mining operation from 1920 to 1990, and may have produced as much as 
80% of the world’s supply. This vermiculite was later found to contain 21-26% asbestos, 
explaining both occupational and environmental asbestos exposures in the Libby 
community (Wake, 1962; Wright, 2002). The Libby mine was closed in 1990 and the last 
ore was shipped to processing plants in 1993, but asbestos-related health problems 
continue to develop for exposed workers and their families. This is primarily due to the 
fact that asbestos related diseases (ARD) have a long latency period of 15-40 years, 
which indicates that many more people will continue to develop ARD in the future.  
 Asbestos fibers are divided into two distinct groups consisting of either straight 
amphibole fibers consisting of double-chain silicates or curved serpentine fibers 
consisting of thin-walled sheet silicates. Libby amphibole (LA) is a combination of 
amphibole fibers and cleavage fragments that include tremolite, actinolite, soda 
tremolite, richterite, and winchite amphiboles (Meeker, 2001). Exposure to LA is 
associated with several ARD including asbestosis, lung cancer, mesothelioma, and 
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pleural plaques (McDonald, 1986; Amandus, 1987a; Amandus, 1987b). In 1999 the 
Agency for Toxic Substance Disease Registry (ATSDR) and the Environmental Protection 
Agency (EPA) conducted studies on respiratory disease in Libby residents and found a 
20% to 40% increase in malignant and nonmalignant respiratory deaths. In particular, 
the asbestosis mortality rate was 40 to 60 times greater than the national average 
(ATSDR, 2000).  
Asbestosis can be defined as bilateral diffuse interstitial fibrosis of the lungs 
caused by the inhalation of asbestos fibers (American Thoracic Society, 1986; 
Craighead, 1982). The pathogenesis of asbestosis begins with the characteristic of 
amphibole fibers like those contained in LA to penetrate deep into the lungs where they 
become lodged in the alveoli (Brody, 1981; Brody, 1983). Here the fibers cause the 
initiation of a chronic inflammatory reaction as the local immune system attempts to 
eradicate the foreign matter (Chang, 1988). Specifically, macrophages are stimulated to 
ingest the fibers and fibroblasts lay down connective tissue to wall off the fibers 
respectively. Eventually the macrophages begin to die as they become subject to the 
natural resistance asbestos has to phagocytosis. As this occurs, cytokines are released 
by the immune system to attract additional macrophages and fibroblasts to further 
deposit fibrous tissue eventually resulting in the creation of a fibrous mass surrounding 
the asbestos fibers (Cutroneo, 2003; Chapman, 2004). 
The deposition of fibrous tissue is a typical response to lung injury. Animals 
suffering from bleomycin-induced pulmonary fibrosis endure a characteristic sequence of 
inflammatory cell migration, edema, cellular proliferation, and accumulation of collagen, 
as occurs in human lungs after similar exposure (Brown, 1988; Lazenby, 1990). 
Following the exposure, the lung will undergo remodeling of the extracellular matrix. 
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Studies show that several changes then occur, in particular there are increases in the 
steady-state levels of type I and III procollagen mRNA (Hoyt, 1988; Swiderski, 1998). 
Whether a similar process occurs in a model of pulmonary fibrosis induced by Libby 
amphibole has yet to be examined. 
Due to its unique composition, the amphibole contained in the Libby vermiculite 
may have characteristics that make its overall health effects different than that of other 
asbestos fibers. Using a mouse model, the purpose of this investigation was to examine 
the fibrotic effects of LA in the lung compared to the effects of crocidolite, a well-
characterized asbestos fiber, and to examine these effects over time. Many individuals in 
the Libby area currently suffer from asbestosis, and the exact mechanism leading to 
progression of the disease has yet to be determined. This study may help to answer 
some of the questions regarding this unknown mechanism by bringing to light some of 
the similarities and differences between LA and crocidolite asbestos. For instance, the 
similarities between the lungs response to either LA or crocidolite can be compared to 
the similarities between the two fiber types. This would identify some of the 
mechanisms involved in the response to LA by referring to some of the known 
mechanisms involved in the response to crocidolite based on fiber properties.  
 
Materials and Methods 
 
Asbestos. A sample of the Libby amphibole was generously provided by the U.S. 
Geological Survey. The amphibole used is a chemical representation from six locations at 
the mine and has been characterized in detail (Wylie, 2000; Gunter, 2003; Meeker, 
2003). This amphibole sample also has a particle size distribution matching air sample 
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size distribution data (Meeker, 2003). Crocidolite asbestos was obtained from the 
Research Triangle Institute (Research Triangle Park, NC). The fiber size distribution of 
both Libby amphibole and crocidolite asbestos has been previously reported (Blake, 
2007). For reference, size parameters of the Libby amphibole sample were 0.61 µm in 
diameter, 7.21 µm in length, with 22.52 for the aspect ratio. Size parameters of the 
crocidolite were 0.16 µm in diameter and 4.59 µm in length, with a 34.05 aspect ratio. 
Samples were freshly prepared in sterile phosphate-buffered saline (PBS, pH 7.4) and 
sonicated before instillation (Putnam, 2008). 
 
Mouse Treatment. All animal protocols were approved by the Institutional Animal Care 
and Use Committee. Mice were exposed to amphiboles according to methods previously 
described (Adamson, 1987). Briefly, pathogen-free 6-8 week old female and male 
C57Bl/6 mice were instilled intratracheally with 100 µg of crocidolite asbestos or Libby 
amphibole in 30µl sterile PBS while under anesthesia. Control mice received only sterile 
PBS. Mice were euthanized 1 week, 1 month, or 3 months after instillation. Treated mice 
were then divided into two groups. The left lung of the mice in the first group was 
removed for RNA isolation, while the right lung was perfused and immersed in 
Histochoice (Amresco, Solon, OH) before being embedded in paraffin. The caudal aspect 
of the left lung of the mice in the second group was removed, rinsed in PBS and 
collagen content quantified by hydroxyproline analysis. The remaining lung tissue was 
snap frozen in liquid nitrogen until protein could be isolated.  Eight to ten mice were 
included in each treatment group. 
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Histology. Fixed lungs were embedded in paraffin and processed into 7µm sections. 
Routine Gomori’s trichrome staining was performed in order to visualize fibrillar collagen 
localization in the lung, and the sections examined under light microscopy. 
 
Inflammation Scoring. Scoring was performed by a board certified veterinary 
pathologist, Donald Gardner at Rocky Mountain Laboratories, MT. 3 to 6 mice from each 
treatment group/time point were scored through the analysis of at least 9 sections per 
mouse. Scores were determined by general appearance and the amount of infiltrating 
lymphocytes as seen by hematoxylin and eosin staining. Scores of mouse sections were 
averaged with numerical values representing the following stages of inflammation: 0 = 
absent, 1 = minimal, 2 = mild, 3 = moderate, and 4 = severe. 
 
RNA Isolation and Quantitative RT-PCR. Lung tissue was homogenized in 1 ml of TRIZOL 
and RNA isolated following the manufacturer’s protocol (Invitrogen, Carlsbad CA). The 
resulting RNA was purified using the RNeasy kit (Qiagen, Valencia, CA) and 
subsequently treated with DNAse (Qiagen). For qRT-PCR, initially first strand synthesis 
of cDNA was accomplished using a First-Strand Synthesis kit (Invitrogen, Carlsbad, CA). 
Target cDNA was subsequently amplified using predesigned TaqMan probes (ABI, Foster 
City, CA) for Collagen 1A1, Collagen 1A2 and Collagen 3A1, as well as probes to detect 
both GAPDH and β-Actin transcripts as controls. qPCR was performed on an iQ5 Optical 
System (Bio-Rad, Hercules, CA). 
 
Hydroxyproline Assay. Quantitation of lung collagen content from exposed and control 
mice was determined by an assay for hydroxyproline content according to methods 
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previously described (Woessner, 1961) with some modifications. Lung tissue was rinsed 
in PBS, minced and hydrolyzed in 1.5 ml of 6N HCl overnight at 110°C. To 5 µl of the 
hydrolysate were added 10 µl of 0.02% methyl red and 2 µl of 0.04% bromothymol 
blue. The sample volume was adjusted to 200 µl with assay buffer (0.024 M Citric Acid, 
0.02 M Glacial Acetic Acid, 0.088 M Sodium Acetate, and 0.085 M NaOH). The 
colorimetric assay was performed by the addition of 100 µl of chloramine T solution and 
incubation at room temperature for 20 minutes. Following incubation, 100 µl of dimethyl 
benzaldehyde solution was added and the solution incubated in a 60°C water bath for 15 
minutes. Absorbance was measured at 550 nM for each lung sample in a 96-well plate 
and quantitation of hydroxyproline was determined by comparison to a standard curve.  
 
Statistical Analysis. Mean values for the hydroxyproline assay were compared by one-
way ANOVA with Newman-Keuls test for multiple comparisons. Results are presented as 
mean values ± SEM. Results from Real-time PCR on triplicate pools of RNA for each 
treatment group were normalized to both Gapdh and β-actin and statistically analyzed 
with a two-tailed t-test on the treatment means. Results are presented as mean fold 
difference ± SEM versus PBS. Inflammation scores were first averaged for each mouse, 
then treatment groups analyzed by one-way ANOVA with a Bonferroni test for multiple 
comparisons. In all cases, significant results were determined by p < 0.05. 
 
Results 
 
C57Bl/6 mice, a strain sensitive to induced fibrosis, were exposed to crocidolite 
asbestos (CRO), Libby amphibole (LA), or sterile phosphate buffered saline (PBS) as a 
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vehicle control by intratracheal instillation. One week, one month, and three months 
after instillation, the mice were sacrificed and lungs removed for analysis.  
Histological examination revealed that collagen deposition around the airways 
was increased in the crocidolite treated animals (collagen appears blue-green in Gomori 
Trichrome-stained sections, indicated by the arrows, Figure 8B, 8E, and 8H), which 
represented the typical pattern of fibrosis seen in animals exposed to this amphibole. By 
three months post instillation, the presence of multi-nucleated giant cells and 
macrophages became apparent in crocidolite-exposed animals (Figure 8H), a further 
indication of the chronic inflammation and fibrosis. The histologic effects seen in LA 
treated mice were similar to those seen in crocidolite treated mice, though these effects 
appeared less severe at all time points examined (Figure 8C, 8F, and 8I). No major 
differences among the three time points were seen in the PBS treatment group (Figure 
8A, 8D, and 8G). Morphology of the airways appeared normal and the alveolar 
architecture was not disordered. In addition, no changes at the pleura of the lungs 
indicative of potential mesothelioma were detected, although that would be unexpected 
at such short time frames. 
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Figure 8: Wild-Type Lung Histology 
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Figure 8 Legend: Histopathology of lungs from C57Bl/6 mice exposed to PBS, CRO, or 
LA (Magnification 200X). Mice were intratracheally instilled for 1 week (A-C), 1 month 
(D-F), or 3 months (G-I) and lung sections were stained with Gomori’s trichrome stain to 
identify the distribution of collagen. Collagen containing areas appear blue-green. The 
lungs of control mice exposed to PBS (A, D, and G) have a much lower level of collagen 
deposition than the lungs of either the CRO exposed mice (B, E, and H) or LA exposed 
mice (C, F, and I). Arrows are used to identify examples of fiber accumulation. 
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Lung sections were also scored for inflammation to determine the severity of 
disease (Table 2). On average, crocidolite exposed mice presented minimal inflammation 
at one week (score of 1.2) and a progressive worsening of the response to mild 
inflammation by three months (score of 1.8). Mice treated with LA, while scored as 
demonstrating minimal inflammation at the one week time point (score of 0.9), were 
evaluated as slightly less involved than the crocidolite exposed animals. The disease 
process in the LA exposed group was maintained at one month after instillation with a 
score of 0.7 and did not appear to worsen over time, as inflammation in the lungs 
appeared to be resolving over time with a final 3 month score of 0.4. These data 
indicated that, as expected, the lungs of mice exposed to either crocidolite or LA 
demonstrated inflammatory response after only one week. Statistical analysis 
demonstrated a significant increase in inflammation for the crocidolite treated mice 
compared to the PBS treated controls at the one month time point only.  Control mice 
instilled with PBS demonstrated minimal to no inflammation at all time points (scores of 
0.0 to 0.1). It is apparent from the histological sections that asbestos exposure 
increases inflammation in both crocidolite and LA treated animals. 
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Table 2: Inflammation Scoring of Wild-Type Lung Tissue 
 
1Inflammation scoring values are as follows: 0.0 = absent, 1.0 = minimal, 2.0 = mild, 
3.0 = moderate, and 4.0 = severe; * = p < 0.05 
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Collagen accumulation and scar tissue production have been shown to play a 
significant role in the development of fibrosis, therefore, quantitative RT-PCR was 
utilized to determine gene expression changes of the type I collagen genes, Col1A1 and 
Col1A2, in response to asbestos exposure (Figure 9). One week after instillation the 
expression of Col1A1 mRNA in the lungs of both crocidolite asbestos and LA exposed 
mice was increased compared to PBS-exposed control mice (Figure 9A). Only LA treated 
mice demonstrated increased expression of Col1A2 at this time point (Figure 9B). One 
month after instillation both Col1A1 and Col1A2 expression in lungs from crocidolite 
asbestos and LA treated mice were increased over that seen in PBS treated mice, but in 
both exposures only Col1A1 expression was significantly increased (Figure 9A and 9B). 
At the three month post-instillation time point, the expression levels of the type I 
collagen genes in mRNA from the crocidolite asbestos and LA treated mice were not 
different from expression levels of the PBS treated group (Figure 9A and 9B). These 
analyses demonstrated that after exposure to crocidolite asbestos and LA, type I 
collagen mRNA synthesis initially increased but returned to baseline levels over time.   
To further demonstrate the idea of a return to baseline collagen levels, analyses 
were performed on the differential expressions of each gene over time (Figure 9, upper 
significance bars). In terms of type I collagen, I found that there is significantly less type 
IA1 collagen mRNA at one month and three months post exposure compared to one 
week for both amphibole treatment groups. I also found there to be a significant 
decrease in type IA2 collagen mRNA over time in the Libby amphibole treatment group. 
This demonstrates that the synthesis of type I collagen mRNA in response to asbestos in 
mice is immediate and begins to fade over time. 
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I also examined changes in gene expression of type III collagen (Figure 9C). The 
qRT-PCR results indicated that there was a significant increase in the expression of 
Col3A1 mRNA at one month post instillation in the LA treated mice and also an increase, 
though not significant, at this time point in Col3A1 mRNA from the crocidolite treated 
mice. By three months post instillation, Col3A1 mRNA levels were still elevated in the 
treatment groups but the increase was no longer significant for the LA treated mice. 
Similar to the type 1 collagen gene mRNA expression profile, the expression of type III 
collagen gene mRNA peaked at the one month time point after amphibole instillation, 
followed by a return to baseline levels. 
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Figure 9: Wild-Type Collagen qRT-PCR 
 
A. 
B. 
C. 
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Figure 9 Legend: Real-Time PCR of pro-collagen types 1A1, 1A2 and 3 mRNA from the 
lungs of C57Bl/6 mice exposed to PBS, CRO, or LA. RNA was isolated from the lungs of 
replicate animals intratracheally 1 week, 1 month, or 3 months after instillation and the 
fold difference of lung pro-collagen 1A1 mRNA (A), pro-collagen 1A2 (B), and pro-
collagen type 3 (C) between the asbestos treated mice and the PBS controls was 
determined. Each experiment was repeated three times.  Results on triplicate pools of 
RNA for each treatment group (n = 10 – 12 per group) were normalized to both Gapdh 
and β-actin and are presented as mean fold difference ± SEM. Both the CRO and LA 
treatment groups have an increased amount of pro- collagen 1A1 mRNA over PBS at 1 
week and 1 month. The LA treatment group also has significantly more pro-collagen 1A2 
mRNA than the PBS group at 1 week. Both the CRO and LA treatment groups had higher 
levels of pro-collagen type 3 at 1 month and 3 month than the PBS group though the 
increase was only significant at 1 month. When looking at changes over time, both LA 
and CRO have significantly more Col1A1 mRNA at one week than at one or three 
months post exposure. LA also has significantly more Col1A2 mRNA at one week than at 
one and three months and more Col3 mRNA at one month than at one week. (* = p < 
0.05, ** = p < 0.01, *** = p < 0.001) 
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Because of the pattern of changes in collagen mRNA expression compared to the 
histologic changes over the time course studied, it was important to examine the 
relationship between type I and III collagen gene expression changes and resultant 
collagen protein levels. Therefore, total collagen content was determined by measuring 
the hydroxyproline content in the caudal aspect of the left lung (Figure 10). One week 
after instillation, hydroxyproline levels in lungs of both the crocidolite and LA treated 
mice were significantly increased over levels seen in the lungs of PBS treated mice 
(Figure 10A).  This increase in hydroxyproline content was also detected at one month 
post-instillation for lungs from the amphibole treated mice compared to the PBS treated 
control mice (Figure 10B). However, by three months post-instillation, the level of 
hydroxyproline in the crocidolite treated mice remained significantly higher than that of 
the PBS treated mice (Figure 10C), while the hydroxyproline level in the LA treated mice, 
though elevated, was not significantly different from the PBS treated mice. There were 
no significant differences in hydroxyproline content in each treatment group over time. 
The increase in collagen protein levels in the treatment groups correlated with the initial 
increase seen in type I collagen mRNA production.  However, the persistence and 
accumulation of collagen protein production was independent of mRNA expression levels 
in crocidolite treated mice, while collagen deposition in LA treated mouse lungs did not 
persist.  These results indicated that the fibrotic response of the murine lung to LA was 
different from the response to crocidolite. 
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Figure 10: Wild-Type Hydroxyproline Assay 
A. 
B. 
C. 
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Figure 10 Legend: Total hydroxyproline content from the lungs of C57Bl/6 mice exposed 
to PBS, CRO, or LA. Mice were intratracheally instilled for 1 week (A), 1 month (B), or 3 
months (C) and collagen content of the left lung was determined by measuring 
hydroxyproline levels in replicate animals. All experiments were done in triplicate. Mean 
values for the hydroxyproline assay were compared by one-way ANOVA with Newman-
Keuls test for multiple comparisons. Results are presented as mean values ± SEM for 
each treatment/time (all groups have n = 10 except the 3 month CRO exposed mice 
with n = 8). The CRO and LA exposed mice had significantly more lung collagen than 
the PBS control (* = p<0.05, ** = p<0.01, *** = p<0.001). There were no significant 
differences in any individual exposure type over time. 
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Discussion 
 
Investigations into asbestos toxicity have been carried out previously on well-
characterized amphiboles such as crocidolite, yet in spite of the increase in knowledge, 
gaps still exist.  Recent studies have suggested a variety of mechanisms by which 
asbestos may induce ill health effects including the chemical and structural properties of 
the fibers, lung fiber burden, fiber uptake by epithelial cells, iron-catalyzed free radicals, 
DNA damage, cytokine release, growth factor release, generation of reactive oxygen 
species, and synergy with tobacco smoke exposure (Kamp, 1999; Manning, 2002). The 
purpose of this investigation was to compare the effects of LA to those of crocidolite in 
order to both determine the differences between the lungs response to either amphibole 
and begin to delineate the mechanism of LA toxicity in terms of fibrotic disease. 
 The effects of crocidolite asbestos have been studied for many years, however 
investigations into the physiological effects of LA are still relatively new (Hamilton, 2004; 
Baldys, 2007; Blake, 2007; Putnam, 2008). The description of the asbestosis found in 
Libby miners and residents has been consistently different than that of patients exposed 
to other amphiboles (Peipens, 2003; Sullivan, 2007). It has been previously suggested 
that these differences could be due to the mixed fiber composition of LA, which is 
different from other types of more extensively studied amphiboles. I used exposure to 
crocidolite asbestos as a well-characterized positive control fiber for comparison in these 
studies, and have demonstrated response differences in both inflammation and collagen 
accumulation after exposure to crocidolite or LA.  The studies presented here showed 
that disease progression differed between the two treatment groups with the crocidolite 
exposed group developing more inflammation over time while inflammation in the LA 
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exposed animals progressively lessened from one week to three months.  Additional 
differences between the groups included an increase in collagen accumulation in mice 
exposed to crocidolite compared to those exposed to LA as demonstrated histologically 
by Trichrome staining and quantitatively by hydroxyproline analysis. Mice exposed to LA 
exhibited slightly less collagen deposition than crocidolite, though this difference was not 
significant. These results are not unexpected, and are probably related to the chemical 
characteristics of LA compared to crocidolite.  As described by both Meeker et al. (2003) 
and Blake et al. (2007), the LA used here was comprised of mixed samples from 
multiple sources at the Libby mine.  The majority of the amphiboles were in the 
winchite-richterite series, with minor components represented by tremolite as 
approximately 6% of the respirable fraction.  Winchite and richterite have not previously 
been assessed for the fibrotic endpoints used in the present study, however, 
examination of richterite in immunologic studies using human macrophage cultures have 
found this amphibole to have a lesser effect compared to crocidolite as a control fiber 
(Collan, 1986). Tremolite asbestos studies in rats have demonstrated pulmonary fibrosis 
development in the time frame studied here (Bernstein, 2005). The small proportion of 
tremolite asbestos in LA may explain the reduced fibrosis seen with LA exposure in our 
mice, thus, our results are consistent with previously published investigations.  As 
mentioned above, these differences may also be responsible for the differences in the 
disease process that develops between individuals exposed to LA and those exposed to 
crocidolite asbestos. 
Initial visualization of mouse lungs after crocidolite exposure via histology 
indicated that noticeable quantities of collagen were associated with increased cellularity 
around the alveoli; more so than what was usually seen deposited for structural support. 
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Morphologically, the increase in cellularity consisted of both fibroblasts and 
macrophages, key members of the initial immune response to the foreign fibers (Chang, 
1988). These cell types are known to express pro-inflammatory cytokines responsible for 
increasing TGF-β expression and thus type I collagen expression (Cutroneo, 2003).  
Areas of lung exposed to LA also showed an increase in both collagen deposition and 
cellularity, however to a lesser degree than the collagen levels seen in the lungs of mice 
exposed to crocidolite. The time points examined were also used to establish a course of 
disease progression. We found that the initial response evaluated at one week consisted 
mainly of mixed cellular inflammation. By one month, fibrosis had become apparent with 
an even greater amount of collagen deposition. At three months, chronic inflammation 
was visualized by the increased presence of multi-nucleated giant cells and activated 
macrophages as well as continued collagen deposition, similar to what is seen in human 
fibrotic diseases (Chapman, 2004). To verify these visual findings the levels of both 
collagen mRNAs and protein were further evaluated. 
Quantification of collagen mRNA confirmed the increased collagen levels seen in 
the trichrome stained lung sections at the early time points.  In particular, the levels of 
collagen1A1 mRNA were increased to a similar extent for both the crocidolite and LA 
exposed mice. However, levels of collagen1A2 mRNA were higher in the LA treated mice 
than mRNA levels in the crocidolite treated animals at the one week time point. This 
may be an indication that the initial response to LA versus crocidolite differed in the 
stimulation of collagen1A2. Transcription of both type I collagen genes is coordinately 
regulated, and there is a 2:1 ratio of pro-mRNA for Col1A1 to Col1A2 transcripts, 
reflecting the 2:1 ratio of the peptides in the mature collagen fibril (Ghosh, 2002; 
Cutroneo, 2003).  However, this coordination is achieved through different TGF-β 
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signaling pathways for the collagen 1A1 and collagen1A2 genes.  Thus, the differential 
effects seen on transcript levels of the collagen 1A2 gene after exposure to LA may be 
due to specific pathway activation.  It is important to note that by the three month time 
point expression of neither collagen mRNA was increased over PBS treatment, even 
though collagen was still visualized histochemically and quantitated by hydroxyproline 
assay. This may have been due to regulation by cytokines (Cutroneo, 2003) or it could 
be due to a decreased activity of collagen proteases as the level of hydroxyproline 
appears to be constant from one month to three months. Therefore existing levels of 
collagen remain constant with minimal degradation or synthesis.  
The hydroxyproline assay was used as a measure of collagen protein expression. 
This assay further confirmed the increased levels of collagen by demonstrating an 
increase in hydroxyproline in lungs of amphibole-exposed mice.  Mice exposed to 
crocidolite had elevated levels of collagen compared to mice exposed LA, again being an 
indication that LA sample used was less effective in inducing fibrosis as crocidolite as 
previously discussed. The amount of collagen accumulated continued to increase at the 
one month time point and remained at a steady level at the three month time point. The 
lack of continued collagen deposition could be due to achievement of steady state 
collagen levels through remodeling, as has been demonstrated in a bleomycin model of 
fibrosis (Swiderski, 1998).  
Previous investigations have demonstrated gene expression changes after a six 
month exposure to crocidolite and LA, as well as an increase in collagen deposition 
(Putnam, 2008; Introduction).  For this study, I have used earlier time points to 
delineate the progression of fibrotic indicators after intratracheal instillation of LA as 
compared to crocidolite, a fiber extensively studied in mouse models. I have 
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demonstrated that both fibers are capable of inducing fibrosis as measured histologically 
and by increased hydroxyproline content of the exposed lungs. The fibrotic reaction 
induced by LA does not reach the level induced by crocidolite within the same time 
course, an expected outcome considering the mixed mineral composition of LA.  A 
difference between human asbestosis in individuals from Libby, MT and the endpoints 
observed in our study is that pleural disease is predominant in individuals exposed to LA, 
whereas the mice in this study did not demonstrate observable pleural changes (Peipins, 
2003). This could have been due to differences in the route or duration of exposure as 
well as the latent period since exposure.  Thus, although the murine model may be an 
imperfect representation of the human disease, it is possible that this model can be used 
to determine some of the differences between LA and other forms of asbestos as well as 
to allow study of the time course of disease progression. This investigation has begun to 
point out some of the differences between LA and crocidolite asbestos, but further study 
needs to be conducted to determine the actual mechanistic differences between the 
two. 
 
Conclusion 
 
 In order to study the fibrotic process using mice, short-term exposures must be 
used, as mice appear to heal over time whereas humans do not. It is important to mimic 
the human disease as much as possible to ensure that any results found may be 
applicable to human pulmonary fibrosis. Results of this short-term study indicated that 
both the inflammatory process and collagen accumulation play the largest roles in 
fibrosis development. Therefore it may be important to look into those genes that 
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influence these processes. Looking back at the long-term microarray study, we focused 
on those extracellular matrix genes whose expression was altered, as they are potential 
candidate genes for further study. We found that Sparc, a gene previously found to play 
a role in bleomycin-induced fibrosis, was upregulated 2.686 fold in crocidolite-exposed 
mice and 3.672 fold in Libby amphibole exposed animals. Based on its upregulation after 
asbestos exposure as well as its implicated involvement in fibrosis development, we 
chose to look further into the role of SPARC in the development of fibrosis. 
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CHAPTER TWO 
Mice Deficient in SPARC Show Decreased Collagen Accumulation After Asbestos 
Exposure 
 
Abstract 
 
Asbestos fibers are toxic substances that can cause serious health problems 
including cancer, asbestosis, and mesothelioma when they become airborne and are 
inhaled. Studies in mice have shown that after asbestos exposure, a complex network of 
cytokines, growth factors, and receptors are involved in initial inflammation and ensuing 
asbestosis. However, it has yet to be determined how genetic differences in these 
factors influence asbestos related disease development in humans. We have used gene 
expression studies in a mouse model to identify potential candidate genes involved in 
asbestos response, one such gene being Sparc. SPARC (secreted protein acidic and rich 
in cysteine) is a matricellular protein involved in tissue repair, extracellular matrix (ECM) 
regulation, cellular proliferation, and cellular adhesion. The ability of SPARC to regulate 
the ECM makes it a novel gene candidate for involvement in the fibrosis that occurs 
after asbestos exposure. The goal of this investigation was to determine the role of 
SPARC in fibrosis development after exposure to crocidolite asbestos or Libby 
amphibole, specifically targeting how lack of SPARC expression can influence ECM 
production. We speculated that SPARC is required for the accumulation of collagen seen 
in asbestos-induced pulmonary fibrosis. C57Bl/6 wild-type and SPARC-null mice were 
instilled intratracheally with crocidolite, Libby amphibole, or PBS for various durations. 
Through real-time PCR, fluorescent staining, and Western Blotting I found that 
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expression of SPARC is increased in both crocidolite and Libby amphibole treated mice 
compared to control. This increase in expression results in higher collagen deposits 
verified both visually through trichrome staining and via hydroxyproline levels. Lack of 
SPARC in these treated mice mitigated the level of collagen deposition. Overall, these 
results indicate that expression of SPARC is a significant step in the development of lung 
fibrosis through the modulation of ECM production. 
 
Introduction 
 
Libby, Montana was the site of a vermiculite mining operation from 1920 to 
1990, and may have produced as much as 80% of the world’s supply. This Libby 
vermiculite was contaminated with asbestos, which subsequently led to both 
occupational and environmental exposures in the Libby community. Libby asbestos (LA) 
is a combination of amphibole fibers that include tremolite, actinolite, soda tremolite, 
richterite, and winchite (Meeker, 2001). Exposure to LA is associated with several 
asbestos related diseases (ARDs) including asbestosis, lung cancer, mesothelioma. 
Asbestos-induced pulmonary fibrosis, or asbestosis, can be defined as bilateral 
diffuse interstitial fibrosis of the lungs caused by the inhalation of asbestos fibers 
(American Thoracic Society, 1986; Craighead, 1982). It primarily occurs after prolonged 
exposure to the fibers through mining, manufacturing, handling, or the removal of 
asbestos fibers (Becklake, 1976). The disease is characterized by a scarring of lung 
tissue around the terminal bronchioles and alveolar ducts (A Medical Dictionary, 2004). 
This scar tissue can cause the thickening of alveolar walls, which will hinder the ability of 
the alveoli to transfer oxygen to the blood and remove carbon dioxide. Individuals who 
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contract this disease suffer from severe dyspnea, which can lead to respiratory failure, 
lung cancer or mesothelioma. In 1999 the Agency for Toxic Substance Disease Registry 
(ATSDR) and the EPA conducted studies on respiratory disease in Libby residents and 
found that the asbestosis mortality rate was 40 to 60 times greater than the national 
average (ATSDR, 2000). 
The development of pulmonary fibrosis involves complex interactions between a 
number of cell types, including epithelial, interstitial, and inflammatory, and cellular 
components like cytokines and the extracellular matrix (Bienkowski, 1995). One class of 
proteins with a potential to modulate fibrosis is the matricellular proteins that bind to 
matrix components as well as to cell surface receptors. A member of the matricellular 
class of secreted proteins with the potential to modulated collagen deposition in 
response to fiber inhalation is SPARC (secreted protein acidic and rich in cysteine), also 
known as osteonectin or BM-40. SPARC has been shown to accumulate in the lung in 
idiopathic pulmonary fibrosis (Kuhn, 1995) and also play a role in collagen deposition in 
bleomycin-induced pulmonary fibrosis (Strandjord, 1999; Savani, 2000). Other members 
of this family of structurally distinct secreted proteins with counteradhesive properties 
include tenascin and the thrombospondins (Sage, 1991). 
SPARC is a 43kD glycoprotein that plays a significant role in tissue repair and 
remodeling through the regulation of cell-matrix interactions (Bornstein, 1995; Reed, 
1996). Expression of SPARC is widespread in developing fetal tissues but in the adult, 
expression occurs in tissues exhibiting a high turnover rate like the gut, skin, and 
glandular tissue (Lane, 1994) and also occurs in tumors (Schulz, 1988). SPARC is 
synthesized in and secreted from platelets, macrophages, fibroblasts, and endothelial 
cells under the regulation of transforming growth factor-β (TGF-β) and platelet-derived 
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growth factor (PDGF) (Jendraschak, 1996; Wrana, 1991). However, in terms of 
pulmonary fibrosis, SPARC has been localized primarily to fibroblasts, epithelial cells, and 
macrophages (Porter, 1995; Puolakkainen, 1999; Reed, 1993; Latvala, 1996). SPARC is 
a calcium-binding glycoprotein that interacts with many ECM components including the 
fibrillar collagens (types I, II, III, and V) as well as type IV, thrombospondin1, 
vitronectin, and fibrinogen fragments D and E (Bradshaw, 2001; Wang, 2006). SPARC 
has also been shown to be a modulator of growth factors involved in fibrosis and has 
also been implicated in the development of cancers (Schiemann, 2003; Framson, 2004; 
Siddiq, 2004). 
Previous investigations into the role of SPARC in bleomycin-induced pulmonary 
fibrosis have shown conflicting results in terms of collagen deposition. It was shown that 
SPARC-null mice demonstrate a decrease in collagen accumulation with low-dose 
bleomycin injury (Strandjord, 1999). However, with a high-dose bleomycin lung injury, it 
was reported that lack of SPARC results in a significant increase in collagen deposition 
(Savani, 2000). Regardless of the dose it appears as though SPARC definitely plays a 
role in fibrotic disease development, therefore we felt it would be important to study the 
effects of a SPARC deficiency in a model of asbestos-induced pulmonary fibrosis. 
 The purpose of this study was to determine the effect of a SPARC deficiency on 
collagen deposition in the murine lung after exposure to LA or crocidolite asbestos. 
Crocidolite was used as a well-documented amphibole fiber for comparison. SPARC-null 
(SP-null) mice on a C57Bl/6 background and wild-type C57Bl/6 (WT) controls were 
intratracheally instilled with either asbestos suspended in phosphate buffered saline 
(PBS) or PBS alone as a vehicle control. The goal of this study is to determine if SPARC 
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plays a role in the regulation of pulmonary fibrosis through the modulation of collagen 
deposition.  
 
Materials and Methods 
 
Asbestos: A sample of the Libby amphibole was generously provided by the U.S. 
Geological Survey. The amphibole used is a chemical representation from six locations at 
the mine and has been characterized in detail (Wylie, 2000; Gunter, 2003; Meeker, 
2003). This amphibole sample also has a particle size distribution matching air sample 
size distribution data (Meeker, 2003). Crocidolite asbestos was obtained from the 
Research Triangle Institute (Research Triangle Park, NC). The fiber size distribution of 
both Libby amphibole and crocidolite asbestos has been previously reported (Blake, 
2007). For reference, size parameters of the Libby amphibole sample were 0.61 µm in 
diameter, 7.21 µm in length, with 22.52 for the aspect ratio. Size parameters of the 
crocidolite were 0.16 µm in diameter and 4.59 µm in length, with a 34.05 aspect ratio. 
Samples were freshly prepared in sterile phosphate-buffered saline (PBS, pH 7.4) and 
sonicated before instillation (Putnam, 2008). 
 
Mouse Treatment: All animal protocols were approved by the Institutional Animal Care 
and Use Committee. Mice were exposed to amphiboles according to methods previously 
described (Adamson, 1987). Briefly, pathogen-free 6-8 week old female and male 
C57Bl/6 WT mice and SPARC-null mice (SP-null) were instilled intratracheally with 100 
µg of crocidolite asbestos or LA in 30µl sterile PBS while under anesthesia. Control mice 
received only sterile PBS as a vehicle control. Mice were euthanized 1 week, 1 month, or 
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3 months after instillation. Treated mice were then divided into two groups. The left 
lung of the mice in the first group was removed for RNA isolation, while the right lung 
was perfused and immersed in Histochoice (Amresco, Solon, OH) before being 
embedded in paraffin. The caudal lobe of the left lung of the mice in the second group 
was removed, rinsed in PBS and collagen content quantified by hydroxyproline analysis. 
The remaining lung tissue was snap frozen in liquid nitrogen until protein could be 
isolated. 
 
Histology: Fixed lungs were embedded in paraffin and sliced into seven µm sections. 
Routine Gomori’s trichrome staining was performed in order to visualize fibrillar collagen 
localization in the lung, and the sections examined under light microscopy. 
 
Fibrosis Scoring: Scoring was performed by a licensed veterinary pathologist (Donald 
Gardner, Rocky Mountain Laboratories, MT). 3 to 6 mice from each treatment 
group/time point were scored through the analysis of at least 9 sections per mouse. 
Scores of mouse sections were averaged with numerical values representing the 
following stages of fibrosis: 0.0 = absent, 1.0 = minimal, 2.0 = mild, 3.0 = moderate, 
and 4.0 = severe. 
 
RNA Isolation: Lung tissue samples were homogenized in 1ml of TRIZOL and RNA 
isolated following the manufacturer’s protocol (Invitrogen, Carlsbad CA). The resulting 
RNA was purified using the RNeasy kit (Qiagen, Valencia, CA) and subsequently treated 
with DNAse (Qiagen, Valencia, CA). 
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Quantitative RT-PCR: RNA isolated from lung tissue was analyzed by quantitative RT-
PCR.  Initially, first strand synthesis of cDNA was carried out using a First-Strand 
Synthesis kit (Invitrogen, Carlsbad, CA). Target cDNA was subsequently amplified using 
predesigned TaqMan probes (ABI, Foster City, CA) for Collagen 1A1, Collagen 1A2, 
Collagen 3, and Sparc as well as probes to detect both Gapdh and β-Actin transcripts as 
controls. PCR was performed on an iQ5 Optical System (Bio-Rad, Hercules, CA). 
 
Protein Isolation: Lung tissue was homogenized in lysis buffer (PBS, Triton X-100, 
sodium desoxycholate, sodium dodecyl sulfate, EDTA, phenylmethylsulphonylfluride, and 
protease inhibitor) and centrifuged to isolate protein. Total protein concentration was 
measured with the Lowry-like DC Protein Assay (Bio-Rad, Hercules, CA). 
 
Western Blotting: Lung protein samples were separated by electrophoresis through 4-
12% Bis-Tris NuPAGE gels (Invitrogen, Carlsbad, CA) then transferred to PVDF 
membrane (Millipore, Billerica, MA). Membranes were blocked in 5% milk in PBS-
Tween20. Specific antibodies for both SPARC (R & D Systems, Minneapolis, MN) and β-
Actin (Santa Cruz Biotechnology, Santa Cruz, CA) were used to detect protein levels, 
which were quantified using chemiluminescence on a Fuji gel documentation system 
(Fujifilm Life Sciences, Stamford, CT). 
 
Immunofluroescence: SPARC expression was detected by incubation with anti-SPARC (R 
& D Systems, Minneapolis, MN) antibodies followed by labeling with Alexa Fluor 568. 
Original magnification was 200X. 
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Hydroxyproline Assay: Quantitation of lung collagen content from exposed and control 
mice was determined by an assay for hydroxyproline content according to methods 
previously described (Woessner, 1961) with some modifications. The lower left lobe was 
rinsed in PBS, minced and hydrolyzed in 1.5ml of 6N HCl overnight at 110°C. To 5µl of 
the hydrolysate were added 10µl of 0.02% methyl red and 2µl of 0.04% bromothymol 
blue. Sample volume was adjusted to 200µl with assay buffer (0.024M Citric Acid, 0.02M 
Glacial Acetic Acid, 0.088M Sodium Acetate, and 0.085M NaOH). The colorimetric assay 
was performed by the addition of 100µl of chloramine T solution and incubation at room 
temperature for 20 minutes. Following incubation, 100µl of dimethyl benzaldehyde 
solution was added and the solution incubated in a 60°C water bath for 15 minutes. 
Absorbance was measured at 550nM for each lung sample in a 96-well plate and 
quantitation of hydroxyproline was determined by comparison to a standard curve.  
 
Statistical Analysis: Mean values for the hydroxyproline assay were compared by one-
way ANOVA with a Newman-Keuls test for multiple comparisons. Results are presented 
as mean values ± SEM. Results from Real-time PCR on triplicate pools of RNA for each 
treatment group were normalized to both Gapdh and β-actin and statistically analyzed 
with a two-tailed t-test on the treatment means. Results are presented as mean fold 
difference ± SEM versus PBS. Densitometry values taken from replicate samples run on 
Western blots were normalized to β-Actin then asbestos treated samples were analyzed 
for percent expression versus the PBS treatment group. A one-way ANOVA with a 
Newman-Keuls test for multiple comparisons was used to verify the significance of the 
mean percent expression values and results are presented as mean values ± SEM versus 
PBS. Inflammation scores were first averaged for each mouse, then treatment groups 
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analyzed by one-way ANOVA with a Bonferroni test for multiple comparisons. In all 
cases, significant results were determined by p < 0.05. 
 
Results 
 
Immunohistochemisty was initially performed to determine if SPARC was 
potentially involved in the development of asbestosis. C57Bl/6 wild-type (WT) mice were 
intratracheally instilled with phosphate buffered saline (PBS) as a control, crocidolite 
asbestos (CRO), or Libby amphibole (LA). Mice were sacrificed after one month and the 
lungs were removed and fixed for immunohistochemistry. Seven-micrometer thick 
sections taken from the lungs of these mice were fluorescently labeled with antibodies 
against SPARC protein (Figure 11). Examination of the fluorescence levels indicated that 
SPARC expression was increased in the lungs of mice exposed with asbestos (Figure 11B 
and 11C) when compared to the PBS treatment group (Figure 11A). These initial results 
indicated that SPARC may be involved in the development of fibrosis after asbestos 
exposure and was therefore worthy of further investigation. 
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Figure 11: 1 Month WT SPARC Immunohistochemistry 
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Figure 11 Legend: Immunohistochemical analysis of WT mouse lungs revealed that 
animals exposed to asbestos showed increased SPARC expression. Though both 
amphibole treatment groups showed heightened SPARC expression, it appeared as 
though CRO treated lungs had slightly more expression than LA treated lungs. This 
observation must be verified via immunoblotting. 
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Quantitative real-time PCR was utilized to determine if the initial protein 
expression level changes were also occurring at the mRNA level. Equal quantities of the 
total cellular mRNA from eight to ten mice were pooled for each treatment group and 
reverse-transcribed into cDNA for real-time analysis (Figure 12). No significant fold 
differences in Sparc mRNA were detected at either the one week or three month 
treatment time points. However, at the one month time point, the level of Sparc mRNA 
was significantly increased in both the CRO treatment group and the LA treatment group 
relative to the PBS control. The increase in Sparc mRNA in response to asbestos 
exposure at one month further implicates the role of SPARC in asbestosis development. 
 91 
Figure 12: Wild-Type SPARC qRT-PCR 
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Figure 12 Legend: Real-Time PCR of Sparc mRNA from the lungs of C57Bl/6 mice 
exposed to PBS, CRO, or LA. Each experiment was repeated three times.  Results on 
triplicate pools of RNA for each treatment group (n = 10 – 12 per group) were 
normalized to both Gapdh and β-actin and are presented as mean fold difference ± 
SEM. Both the CRO and LA treatment groups had a significantly increased amount of 
Sparc mRNA compared to the PBS treatment group at one month. When looking at 
changes over time, both LA and CRO treated groups had significantly more Sparc mRNA 
at one month than at one week or three months post exposure. (* = p < 0.05, ** = p 
< 0.01, *** = p < 0.001) 
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Western immunoblotting was necessary to confirm the increase in SPARC protein 
expression seen via immunohistochemistry. Equivalent quantities of total cellular protein 
isolated from the lungs of eight to ten WT mice per treatment group were pooled and 
analyzed for levels of SPARC (Figure 13).  The level of SPARC protein was significantly 
increased at one week for both asbestos exposure groups. By one month the expression 
of SPARC in the LA treatment group was still significantly increased when compared to 
the PBS treatment group but there was no longer any measurable difference in the CRO 
treatment group. This difference in the LA treatment group was no longer detectable by 
three months. The increased levels of both SPARC protein and mRNA provide strong 
evidence that SPARC could play a role in the development of asbestosis-induced fibrosis, 
especially at one week and one month after exposure. 
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Figure 13: Wild-Type SPARC Protein Expression 
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Figure 13 Legend: Immunoblotting of SPARC protein from the lungs of C57Bl/6 mice 
exposed to PBS, CRO, or LA. Each blot was repeated three times.  Results on triplicate 
pools of RNA for each treatment group (n = 10 – 12 per group) were normalized to β-
actin and are presented as the mean percent expression versus PBS ± SEM. Both the 
CRO and LA treatment groups had a significantly increased amount of SPARC protein 
compared to the PBS treatment group at one week after exposure. By one month post-
exposure only the LA treated group had significantly more SPARC than PBS and by three 
months SPARC levels for both treatment groups return to PBS levels. When looking at 
changes over time, CRO treated lungs had significantly more SPARC at one week than 
one month and LA treated lungs had significantly more SPARC at one week than at 
three months. (* = p < 0.05, ** = p < 0.01, *** = p < 0.001) 
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SPARC-null (SP-null) mice were utilized to determine more specifically what role 
SPARC is playing in the induction of asbestosis. Eight to ten WT and SP-null mice were 
again given asbestos (CRO and LA) or PBS via intratracheal instillation, sacrificed at one 
week, one month, and three months after exposure, and fixed for histology (Figure 14 
to Figure 16). When compared to their PBS treated counter parts (Figures 14, 15, and 
16 A and D), the CRO and LA treated WT (Figures 14, 15, and 16 B and C) and SP-null 
(Figures 14, 15, and 16 E and F) mice appeared to develop fibrosis at all time points, as 
evident by the ensuing inflammation.  
After one week of exposure, histological examination revealed similar fibrosis 
development between the WT (Figure 14A to 14C) and SP-null (Figure 14D to 14F) 
treatment groups with the exception of the amount of collagen being deposited around 
the airways of the CRO treated WT mice (Figure 14B: arrows, blue stain) and LA treated 
WT mice (Figure 14C). This was also apparent at one month after exposure with much 
more collagen being deposited around the airways of asbestos treated WT mice (Figure 
15B and 15C) than the airways of SP-null mice (Figure 15D to 15F) and the WT PBS 
treated mice (Figure 15A). By three months post exposure, the difference in collagen 
deposition was still apparent in the LA treated WT (Figure 16C) mice and the WT CRO 
exposed animals (Figure 16B) who still had much greater levels of collagen being 
deposited around the airways than their SP-null LA (Figure 16F) and CRO (Figure 16E) 
exposed counter parts.  
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Figure 14: 1 Week Wild-Type/SPARC-null Lung Histology 
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Figure 14 Legend: Gomori Trichrome-stained 7 µM sections of mouse lungs from 
C57Bl/6 WT and SP-null mice instilled for one week with crocidolite asbestos (CRO), 
Libby amphibole (LA), or sterile saline (PBS) as a vehicle control for comparison (200X 
original magnification).  Blue-green staining indicates collagen deposition and arrows 
point to areas of increased accumulation. The airways of the amphibole exposed WT 
mice showed much higher levels of collagen accumulation than the SP-null mice, though 
both mouse strains showed signs of increased inflammation. 
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Figure 15: 1 Month Wild-Type/SPARC-null Lung Histology 
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Figure 15 Legend: Gomori Trichrome-stained 7 µM sections of mouse lungs from 
C57Bl/6 WT and SP-null mice instilled for one month with crocidolite asbestos (CRO), 
Libby amphibole (LA), or sterile saline (PBS) as a vehicle control for comparison (200X 
original magnification).  Blue-green staining indicates collagen deposition and arrows 
point to areas of increased accumulation. As at one week, the airways of the amphibole 
exposed WT mice showed much higher levels of collagen accumulation than the SP-null 
mice, and both mouse strains showed signs of increased inflammation. 
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Figure 16: 3 Month Wild-Type/SPARC-null Lung Histology 
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Figure 16 Legend: Gomori Trichrome-stained 7 µM sections of mouse lungs from 
C57Bl/6 WT and SP-null mice instilled for three months with crocidolite asbestos (CRO), 
Libby amphibole (LA), or sterile saline (PBS) as a vehicle control for comparison (200X 
original magnification).  Blue-green staining indicates collagen deposition and arrows 
point to areas of increased accumulation. As with both previous time points, airways of 
the amphibole exposed WT mice showed much higher levels of collagen accumulation 
than the SP-null mice, and again both mouse strains showed signs of increased 
inflammation. 
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Histology sections were also scored on a scale of inflammation to further 
determine if the lack of SPARC altered the development of fibrosis after asbestos 
exposure (Table 3). Dr. Donald Gardner, a pathologist at Rocky Mountain Laboratories, 
performed the scoring. No significant differences were found when comparing WT and 
SP-null mice for each time and treatment. The similar inflammation scores between the 
WT and SP-null mice indicated that the mice lacking SPARC still develop the 
inflammatory response, regardless of the difference in the levels of collagen deposition. 
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Table 3: Inflammation Scoring of Wild-Type/SPARC-null Lung Tissue 
 
1Inflammation scoring values are as follows: 0.0 = absent, 1.0 = minimal, 2.0 = mild, 
3.0 = moderate, and 4.0 = severe. There were no significant differences found between 
WT and SP-null mice for each treatment group at any time point. 
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Quantitative real-time PCR was used to verify that the differences in collagen 
levels seen in the trichrome stained lung sections also occurred at the mRNA level. 
Specifically the levels of collagen types I and III were evaluated. As before, equal 
quantities of total cellular mRNA from eight to ten mice were pooled for each treatment 
group for the SP-null mice and reverse-transcribed into cDNA for real-time PCR analysis 
(Figures 17). When evaluating only the SP-null animals, it was concluded that there 
were no apparent differences in the levels of Col1A1 mRNA in the SP-null mice exposed 
to asbestos compared to the PBS exposed controls (Figure 17A). There were, however, 
significant decreases in the expression of Col1A2 in the SP-null mice exposed to LA at 
both the one week and three month time points (Figure 17B). Finally, evaluation of type 
III collagen identified that expression in SP-null mice was significantly increased for the 
CRO treatment group at the one month time point and increased, though not 
significantly so, the three month time point (Figure 17C). Also when comparing 
differences between time points, expression of type III collagen mRNA was significantly 
increased at one month post-exposure compared to one week.  
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Figure 17: SP-null Collagen qRT-PCR 
A. 
B. 
C. 
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Figure 17 Legend: Real-Time PCR of Collagen mRNA from the lungs of SP-null mice 
exposed to PBS, CRO, or LA. Each experiment was repeated three times.  Results on 
triplicate pools of RNA for each treatment group (n = 10 – 12 per group) were 
normalized to both Gapdh and β-actin and are presented as mean fold difference ± 
SEM. Significant differences in collagen mRNA expression occur in the CRO treatment 
group at one month post-exposure where there was a significant increase in type III 
collagen mRNA when compared to the PBS treatment group. When looking at changes 
over time, CRO exposed animals had significantly more type III collagen mRNA at one 
month than at one week. (* = p < 0.05, ** = p < 0.01, *** = p < 0.001) 
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The SP-null results were also compared with data from the exposure of wild-type 
mice previously presented in Chapter 1 for both the CRO and LA treatment groups 
(Figure 18). The expression levels of collagen type I alpha 1 (Col1A1) mRNA was 
significantly higher in WT mice exposed to either CRO or LA relative to their SP-null 
counterparts at both the one week and one month time points (Figure 18A and 18B). 
The expression levels of collagen type I alpha 2 (Col1A2) mRNA were also significantly 
increased in the WT mice versus the SP-null mice at the one week time point in the LA 
treatment group (Figure 18D). There were no differences in Col1A2 expression between 
the WT and SP-null mice in the CRO treatment group at any time point (Figure 18C). 
Expression of type III collagen (Col3) in WT mice was significantly increased when 
compared to the SP-null mice for the LA treatment group at the one month time point 
(Figure 18F). Again there were no significant differences in the CRO treatment group 
between the two strains for type III collagen mRNA expression (Figure 18E). The lack of 
a change in Col3 mRNA in the CRO exposed mice may indicate that another protein is 
compensating for the lack of SPARC in the SP-null animals. The differences in type I 
collagen between the WT and SP-null mice further demonstrated that SPARC plays an 
important role in asbestosis development, and this role appears to center around the 
presence of collagen. 
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Figure 18 Wild-Type vs SPARC-null Collagen qRT-PCR 
 
 
 
 
 
A. 
C. 
F. 
D. 
E. 
B. 
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Figure 18 Legend: Real-Time PCR of Collagen mRNA from the lungs of SP-null mice  
versus WT mice exposed to PBS, CRO, or LA. Data were previously presented in Figures 
9 (WT) and 17 (SP-null). There were significant decreases in type I alpha1 collagen 
mRNA expression in the SP-null mice of both amphibole treatment groups when 
compared to their WT counterparts at both one week and one month time points. There 
was also a significant decrease in type I alpha2 collagen mRNA expression at one week 
and type III collagen expression at one month in the SP-null versus WT mice of the LA 
treatment group. (* = p < 0.05, ** = p < 0.01, *** = p < 0.001) 
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To further confirm the role of SPARC as a regulator of collagen deposition in the 
lung after asbestos exposure, the hydroxyproline assay was utilized to quantify the total 
amount of collagen protein present in the lung (Figure 19). The levels of total collagen 
in the SP-null mice were for the most part constant regardless of treatment. The only 
difference occurred at one month post-exposure. At this time point, lungs from the CRO 
treated animals had significantly more total hydroxyproline content than the PBS 
controls. In addition lungs from the CRO treatment group demonstrated a significant 
increase in total hydroxyproline content from the one week to one month time points. 
However, hydroxyproline levels returned to baseline by three months after exposure. 
Compared to WT mice, it appeared that less collagen accumulated in the SP-null lung 
after asbestos exposure, further implicating SPARC for a role in the development of 
asbestos-induced fibrosis through the modulation of collagen deposition in the lung.  
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Figure 19: SPARC-null Hydroxyproline Assay 
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Figure 19 Legend: Total hydroxyproline content from the lungs of SP-null mice exposed 
to PBS, CRO, or LA. Mice were intratracheally instilled for 1 week, 1 month, or 3 months 
and collagen content of the left lung was determined by measuring hydroxyproline levels 
in replicate animals. All experiments were done in triplicate. Results are presented as 
mean values ± SEM for each treatment/time (all groups have n = 9-10). Only the one 
month CRO exposed mice had significantly more hydroxyproline content than the PBS 
controls. (*** = p<0.001). There was also a significant increase in total hydroxyproline 
in the CRO treatment group at the one month time point compared to one week. 
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To confirm that less collagen accumulated in the SP-null lungs, analysis was 
performed on the differences between total hydroxyproline in the WT and SP-null lungs. 
The WT data were previously presented in Chapter 1. At all three time points the levels 
of total collagen were significantly lower in the SP-null mice compared to the WT mice in 
both the CRO and LA treatment groups (Figure 20). This evidence in addition to the 
trichrome staining and decreased levels of type I collagen mRNA demonstrated that 
SPARC plays a significant role in the deposition of collagen in the lung in response to 
asbestos exposure. Mice lacking SPARC still developed fibrosis in response to amphiboles 
though it may be less severe due to less collagen in the lung, thereby making respiration 
easier. 
Analysis was also performed on no-treatment (NT) controls to determine if the 
lungs were reacting to the PBS vehicle control. No significant differences were found 
between these groups and their PBS treated counterparts. However, a significant 
decrease was seen in the NT group at three months in the SP-null mice compared to WT 
mice, further demonstrating the decreased ability of the SP-null lung to accumulate 
collagen.  
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Figure 20: Wild-Type vs. SPARC-null Hydroxyproline Assay 
A. 
B. 
C. 
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Figure 20 Legend: Total hydroxyproline content from the lungs of SP-null mice versus 
WT mice exposed to PBS, CRO, or LA. Data were previously presented in Figures 10 
(WT) and 19 (SP-null). Results are presented as mean values ± SEM for each 
treatment/time (all groups have n = 8-10). At all time points there was a significant 
decrease in total hydroxyproline in the amphibole treated SP-null mice versus their WT 
counterparts. (* = p<0.05, ** = p<0.01, *** = p<0.001).  
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Discussion 
 
 The data presented in Chapter 1 demonstrated that intratracheal instillations of 
asbestos cause asbestosis in vivo, thereby providing a model of fibrosis for further 
study. Initial exploration into this model of disease identified SPARC as a candidate 
protein based on its involvement in cell-matrix interactions. I have demonstrated that 
SPARC mRNA and SPARC protein are induced in an asbestos model of pulmonary 
fibrosis. The known function of SPARC as a regulator of the extracellular matrix in 
remodeling tissues (Lane, 1994; Reed, 1996) as well as the previously reported increase 
in total collagen (Smartt, 2008: Chapter 1), implied that SPARC may be playing a 
substantial role in fibrosis development in terms of collagen accumulation. Here, I show 
that lack of SPARC may decrease the severity of fibrosis since significantly less collagen 
is deposited around the airways of asbestos exposed SP-null mice compared to their WT 
counterparts. 
 Even though its specific role in response to asbestos in the lung is not fully 
understood, previous studies implying the ability of SPARC to alter collagen deposition in 
the bleomycin-induced fibrotic lung make it a candidate for study in the development of 
asbestosis. My results showed that SPARC expression was increased in lungs exposed to 
asbestos. Initially it appeared that the levels of SPARC protein were increased via 
immunostaining of fibrotic lung sections. This was later confirmed at one week post 
exposure by immunoblotting. I also found that the expression of Sparc mRNA was 
increased at one month in asbestos exposed animals. Therefore it appeared that the 
initial response to the presence of asbestos was a decrease in the rate of SPARC protein 
elimination. By one month after amphibole exposure, more Sparc mRNA was being 
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transcribed but a correlating increase in the translation into SPARC protein was not 
observed in the CRO exposed mice. A possible explanation for this could be that there 
was a higher turnover rate of SPARC protein, or that there could be an increase in 
posttranscriptional regulation.  
Because of the increase in protein expression after one week post-exposure, 
more SPARC may be bound to the TGF-β receptor complex, which could account for the 
increase in collagen expression observed in Chapter 1. Previous studies have found that 
TGF-β plays a significant role in the development of pulmonary fibrosis (Broekelmann, 
1991; Denis, 1994; Toti, 1997). Several studies have also shown that levels of TGF-β are 
increased as well as activated in the presence of asbestos (Liu, 2001; Sullivan, 2008; 
Pociask, 2004), meaning that TGF-β is bound to its receptor complex and initiates one of 
several signaling cascades. The binding of SPARC to this receptor complex in addition to 
TGF-β may have the ability to activate the TGF-β signaling cascades responsible for the 
induction of collagen transcription (Francki, 2004). Therefore, it may be prudent for 
future studies to determine the extent to which SPARC is bound to the TGF-β receptor 
complex. 
 The data presented in Chapter 1 (Smartt, 2008) indicated that both the 
expression of type I collagen mRNA and total lung collagen protein content were 
significantly increased in C57Bl/6 WT lungs exposed to amphibole asbestos. This mirrors 
similar results in rats and hamsters exposed to bleomycin (Phan, 1980; Quinones, 1986; 
Clark, 1980). This trend does not occur in SP-null animals on a C57Bl/6 background. I 
found that SP-null animals exposed to asbestos did not exhibit a significant increase in 
total collagen content, as measured by hydroxyproline content, when compared to PBS 
controls. The only exception to this was the crocidolite treatment group at one month. It 
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is apparent that at one month, the SP-null lung was responding to the presence of CRO 
asbestos through the synthesis of collagen, however, when compared with their WT 
counterparts, SP-null mice had significantly less collagen accumulation in the lung after 
exposure to asbestos at all time points. This decrease was similar to that seen after low-
dose bleomycin exposure in SP-null mice on a C57Bl/6 x 129 background (Strandjord, 
1999). It may be interesting to determine if this same study repeated in a SP-null mice 
on a 129 background would produce results similar to the high-dose bleomycin exposure 
investigation (Savani, 2000). 
 Type I collagen is the form of collagen found in most connective tissues. It is a 
triple-stranded molecule used to strengthen and support many bodily tissues such as 
cartilage, bone, and skin. There are two main components that make up this type of 
collagen and they are pro-alpha1 and pro-alpha2 encoded by the genes Col1A1 and 
Col1A2 respectively. Pro-alpha1 is the major component of type I collagen and is 
present in a 2:1 ratio with its pro-alpha 2 counterpart. Type III collagen is also found in 
connective tissues, often in conjunction with type I collagen. The different responses in 
the expression of these collagen mRNAs, especially Col1A2 and Col3, between the CRO 
asbestos exposure group and LA exposure group, regardless of WT or SP-null strain, 
further demonstrated the differences between the two amphibole forms. Much more 
research is needed to determine why these differences are occurring. Several 
possibilities exist including differences in fiber size, surface charge, and composition. To 
begin to try to answer some of these questions, I evaluated total collagen content in 
both WT and SP-null lungs exposed to the elutriated, shorter LA fibers. These results are 
presented in Appendix A.  
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 Overall, the reduction of the fibrotic response in the SP-null mice could be due to 
either a decreased synthesis of collagen, an increased degradation of collagens, or 
maybe both. It could also be that the collagen synthesized in the SP-null mouse is much 
more fragile than WT collagen. Also, it has been shown that SPARC plays a role in the 
cellular remodeling of collagen (Iruela-Arispe, 1996). Therefore, in mice lacking SPARC, 
failed remodeling or fragile proteins would facilitate collagen degradation. This could 
explain the significant collagen decrease seen in the SP-null mice compared to WT mice 
after asbestos exposure, along with the decrease in collagen mRNA transcription. If the 
cells in the lungs of SP-null animals have a hindered ability to deposit collagen around 
the intruding asbestos fibers, decreased scar tissue formation would result and therefore 
oxygen transfer would improve regardless of the level of inflammation. 
 Though SPARC is important to the deposition of collagen in the fibrotic response, 
there was still an increase in lung collagen content seen at one month post CRO 
exposure in the SP-null mice. It has previously been shown that the morphology of the 
SP-null mouse lungs are normal (Strandjord, 1999) even though SPARC is known to play 
a role in pulmonary development (Sage, 1989; Strandjord, 1995). Aside from any subtle 
differences that may exist in the SP-null lung, it is apparent that another protein or 
proteins may compensate for SPARC in lung development. These proteins could include 
some of those with a high degree of homology to SPARC such as QR-1 (Casado, 1996) 
or Hevin (Girard, 1995; Soderling, 1997) also known as SC-1 or SPARC-like protein 1. 
Several studies have experimented with Hevin in particular and found that it functions 
similar to SPARC in the inhibition of cell attachment and spreading (Girard, 1996) and 
also that its expression is increased in the developing SPARC-null lung (Soderling, 1997). 
In order to determine if Hevin was compensating for SPARC in the SP-null lung exposed 
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to asbestos, I investigated Hevin expression levels in exposed lungs. These results can 
be found in Appendix B. 
I have shown that in the response to a fibrosis-inducing insult like asbestos in 
the lung, WT C57Bl/6 present with significant increases not only in collagen synthesis 
and accumulation but also in SPARC expression. In the absence of this expression I have 
found that the fibrotic response of the lung after asbestos exposure is muted in terms of 
collagen deposition around the airways. However, the lack of SPARC does not reduce 
the level of inflammation in the lung. It may therefore be prudent to not only diminish 
SPARC expression in animals exposed to asbestos, but to also treat them with an anti-
inflammatory agent to reduce the immune response as well. 
 
Conclusion 
 
Exposure to asbestos causes an increase in collagen accumulation in response to 
the presence of foreign fibers in the lung. A lack of SPARC in mice treated with CRO or 
LA decreased the amount of collagen accumulation in the lung, further supporting the 
idea that SPARC plays a significant role in the development of pulmonary fibrosis. 
Therefore, SPARC is a potential therapeutic target in humans suffering from fibrotic 
diseases. The next step will be to determine if the silencing of SPARC after an individual 
has been exposed to an insult like asbestos will reverse collagen accumulation in the 
lung or just slow future deposition. This is explored in the following Chapter. 
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CHAPTER THREE 
The Effect of SPARC Knockdown on Collagen Production in an Asbestos-Induced Model 
of Pulmonary Fibrosis 
 
Abstract 
 
 Pulmonary fibrosis is a disease that affects millions of people worldwide. As of 
yet, treatments for the disease only help to improve quality of life but do not cure the 
disease itself. In order to begin to develop a cure, the process by which the disease is 
manifested must be interrupted. Specifically, both the inflammatory process and scar 
tissue formation must be inhibited. One step in that direction is the inhibition of the 
production of the matricellular protein SPARC (secreted protein acidic and rich in 
cysteine). I have previously shown that SPARC-null mice exposed to the fibrosis-inducing 
agent asbestos do not have the same increased level of collagen deposition in the lung 
as wild-type mice. The purpose of this investigation was to discover if the inhibition of 
SPARC in wild-type mice already demonstrating fibrosis will cause a similar reduction in 
collagen accumulation. Through the use of RNA interference, I have found that 
administration of SPARC small interfering RNA (siRNA) to animals with fibrosis decreased 
total collagen. However, the results of this study are preliminary and this topic needs 
further research before the true therapeutic potential of SPARC siRNA as a therapy can 
be determined.  
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Introduction 
 
 Asbestosis is a form of progressive pulmonary fibrosis induced by the inhalation 
of asbestos fibers (American Thoracic Society, 2004). Characteristics of the disease 
include both an inflammatory reaction with an infiltration of lymphocytes and 
macrophages as well as the increased proliferation of fibroblasts and increased 
accumulation of interstitial collagen and scar tissue in the alveoli (Ziesche, 1999). The 
development of scar tissue is caused by the overproduction and deposition of types I 
and III collagen by fibroblasts (Oriente, 2000).  
Fibroblasts play crucial roles in the generation, deposition, and remodeling of the 
extracellular matrix during fibrosis development (Clark, 1995). After asbestos exposure, 
fibroblasts are recruited to the lung by the release of inflammatory mediators, TGF-β, 
and Platelet Derived Growth Factor (PDGF). Here they are stimulated by growth factor 
release to produce extracellular matrix components such as collagen and fibronectin 
(Clark, 1995; Singer, 1999). Typically, once an insult is destroyed through phagocytosis, 
the excess collagen is degraded by proteolytic enzymes such as MMPs (matrix 
metalloproteinases) secreted by both fibroblasts and macrophages (Mignatti, 1995). 
Unfortunately, asbestos trapped in the lung cannot be degraded so collagen continues 
to accumulate and cause scar tissue formation. It is therefore necessary to discover a 
mechanism to slow or stop collagen accumulation in the lung after asbestos exposure. 
One gene with the ability to alter levels of collagen deposition in the fibrotic lung is 
Sparc (Chapter 2; Strandjord, 1999; Savani 2000). 
 SPARC (secreted protein acidic and rich in cysteine), a matricellular protein 
involved in extracellular matrix regulation, has been shown to play a significant role in 
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fibrosis development. Studies have found SPARC to be over expressed in several fibrotic 
disorders including asbestosis (Smartt, 2008), scleroderma (Zhou, 2002), pulmonary 
fibrosis (Kuhn, 1995), renal interstitial fibrosis (Pichler, 1996), hepatic cirrhosis (Frizell, 
1995), and atherosclerotic vascular lesions (Dhore, 2001). Though the role of SPARC in 
these disorders is not clear, it may be that SPARC is stimulating the TGF-β signaling 
pathways involving Smad2/3 or JNK (Schiemann, 2003; Francki, 2004). This would 
cause an increased transcription of collagen, a key component of the fibrotic response. 
Using SPARC-null mice, previous studies have indicated that lack of SPARC in the 
lung leads to a diminished amount of collagen deposition in several models of pulmonary 
fibrosis (Chapter 2; Strandjord, 1999). SPARC-null mesangial cells have also been shown 
to display a decreased expression of both TGF-β1 and type I collagen until exogenous 
SPARC is added (Francki, 1999). Based on these observations, SPARC appears to have 
the ability to indirectly regulate collagen expression through its influence on the TGF-β 
signaling system in addition to its ability to directly bind collagen. Therefore, based on 
its ability to regulate collagen deposition in fibrotic disorders, SPARC is a candidate to 
target for the treatment of fibrosis. 
 In order to use the ability of SPARC to alter the expression of collagen for the 
treatment of fibrotic disorders, it must be determined if SPARC inhibition will can prevent 
or even reverse excess collagen deposition in those already suffering from fibrosis. 
Essentially the question becomes: can the inhibition of SPARC expression in a fibrotic 
model change the existing excess levels of collagen? Here I examine whether the 
inhibition of SPARC expression with small interfering RNA (siRNA) can influence the level 
of collagen deposition after asbestos exposure both in vitro using primary mouse lung 
fibroblasts and in vivo using C57Bl/6 wild-type mice.   
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Materials and Methods 
 
Asbestos: Crocidolite asbestos was obtained from the Research Triangle Institute 
(Research Triangle Park, NC). The fiber size distribution of the asbestos has been 
previously reported (Blake, 2007). For reference, size parameters of the crocidolite were 
0.16 µm in diameter and 4.59 µm in length, with a 34.05 aspect ratio. Samples were 
freshly prepared in sterile phosphate-buffered saline (PBS, pH 7.4) and sonicated before 
in vivo instillation (Putnam, 2008). CRO fibers were sterilized under UV light, suspended 
in sterile PBS, and triturated twenty times through a 22-gauge needle for in vitro 
studies. 
 
Lentivirus Generation: Pre-designed SPARC siRNA plasmids contained in bacterial 
glycerol stocks were obtained from Sigma Adrich (Saint Louis, Missouri). Agar plates 
containing ampicillin as a selection agent were streaked with a small amount of the 
siRNA glycerol stocks. LB broth, also containing ampicillin, was inoculated with one 
colony selected from the agar plate. After incubation, plasmid DNA was isolated from 
the broth using a Qiagen Plasmid Midi Kit (Valencia, CA) and following the 
manufacturer’s instructions. The plasmid DNA was then co-transduced with a ViraPower 
Packaging Mix in 293FT cells again following the manufacturer’s instructions (Invitrogen, 
Carlsbad, CA). Virus was harvested from the media of the 293FT cells 72 hours post-
transduction and stored at -80°C until ready for use. 
 
Isolating Primary Fibroblasts: Fibroblasts were isolated from C57Bl/6 wild-type mice 
according to the procedure published in Migliaccio et al., 2005. Briefly, the lungs were 
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harvested from the mice and minced, then treated with collagenase. Digestion was 
stopped after the addition of serum and the cell suspension was layered on to a 
discontinuous Percoll gradient. Following centrifugation, the fibroblast/epithelial cell layer 
was removed and the cells washed in complete DMEM. The pellet was then 
resuspended in complete DMEM cultured at 37oC in 5% CO2. Cells were subcultured at 
a 1:3 dilution when they were approximately 90% confluent. 
 
Cell Culture: Primary fibroblasts were cultured in complete Dulbecco’s Modified Eagle 
Medium (high glucose DMEM, 10% Fetal Bovine Serum, 1% Antibiotic/Antimycotic, and 
1% sodium pyruvate: VWR, West Chester, PA) at 37oC in 5% CO2. Primary cultures 
used were between passages 2 and 10 and typically the cells would double every 24 
hours. 293FT cells were grown according to the manufacturer’s instructions (Invitrogen, 
Carlsbad, CA). 
 
Determining MOI: All 5 viruses used were titered according to the manufacturer’s 
protocol (Invitrogen, Carlsbad, CA). Primary mouse lung fibroblasts at 60% confluence 
were grown in 6-well plates and treated with 2000, 4000, 6000, 8000, or 10,000 titered 
units (TU) of one of four SPARC siRNA viruses: 349, 350, 351, and 352. After 24 hours 
the viruses were removed and cells cultured for another 24 hours in complete media. 
Protein was harvested at the completion of the final incubation and analyzed for percent 
expression versus no virus treatment.  
 
In vitro Virus Treatment: Primary mouse lung fibroblasts were cultured to 60% 
confluency then exposed to 5µg/cm2 CRO or an equivalent volume of PBS for 6, 12, or 
24 hours. Upon completion of the asbestos incubation, the media was replaced and no 
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virus (NV), non-target virus (-CNT), or virus 350 (833.33 TU/cm2 – as determined by the 
MOI) was added to the new media. 24 hours later the virus containing media was 
removed and replaced with fresh media. Cells were harvested 24 hours later. 
 
Sircol Assay: The Sircol Assay was performed according to the manufacturer’s 
instructions (Biocolor, Carrickfergus, Northern Ireland). Briefly, treated fibroblasts were 
harvested by scraping in sterile PBS. The cells were sonicated for 30 seconds, mixed 
with the dye reagent, and centrifuged. Unbound dye was decanted and the remaining 
collagen bound dye was treated with the dye release reagent. Absorbance was then 
measured at 540nm. 
 
Immunocytochemistry: Primary mouse lung fibroblasts were cultured on sterile 
coverslips for immunocytochemical analysis. At the completion of the experiment, the 
cells were fixed in 3% hydrogen peroxide in ice cold methanol. Cells were blocked in 4% 
Normal Rabbit Serum. SPARC expression was detected by incubation with anti-SPARC 
antibodies (R & D Systems, Minneapolis, MN) followed by labeling with Rabbit anti-Goat 
Alexa Fluor 568. Original magnification was 200X. 
 
Mouse Treatment: All animal protocols were approved by the Institutional Animal Care 
and Use Committee. Mice were exposed to crocidolite according to methods previously 
described (Adamson, 1987). Briefly, pathogen-free 6-8 week old female and male 
C57Bl/6 WT mice were instilled intratracheally with 100 µg of crocidolite asbestos in 30µl 
PBS. Control mice received only PBS. Two months after asbestos instillation, mice were 
intratracheally instilled with 150,000 titered units of virus in 30µl complete media. Mice 
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were euthanized 3 months after asbestos instillation. The lungs of treated mice were 
then divided for RNA isolation, histology, protein isolation, and for the hydroxyproline 
assay. The section of lung used for each analysis was held constant.  
 
Histology: Lungs were perfused and immersed in Histochoice (Amresco, Solon, OH) as a 
fixative. Fixed lungs were then embedded in paraffin and sliced into 7µm sections. 
Routine Gomori’s trichrome staining was performed in order to visualize fibrillar collagen 
localization in the lung, and the sections examined under light microscopy. 
 
RNA Isolation: Lung tissue samples were homogenized in 1ml of TRIZOL and RNA 
isolated following the manufacturer’s protocol (Invitrogen, Carlsbad CA). The resulting 
RNA was purified using the RNeasy kit (Qiagen, Valencia, CA) and subsequently treated 
with DNAse (Qiagen, Valencia, CA). 
  
Protein Isolation: Upon removal from the mouse, lung samples were snap frozen in 
liquid nitrogen. Lung tissue was then homogenized in lysis buffer (0.1% Triton X-100, 
12.6mM sodium desoxycholate, 3.47mM sodium dodecyl sulfate, 1mM EDTA, 2mM 
phenylmethylsulphonylfluride, and protease inhibitor in PBS; Roche, Indianapolis, IN) 
and centrifuged to isolate protein. For in vitro isolation, cells were immersed in lysis 
buffer and scraped from the flask bottom. Total protein concentration was measured 
with the Lowry-like DC Protein Assay (Bio-Rad, Hercules, CA).  
 
Western Blotting: Lung protein samples were separated by electrophoresis through 4-
12% Bis-Tris NuPAGE gels (Invitrogen, Carlsbad, CA) then transferred to PVDF 
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membrane (Millipore, Billerica, MA). Membranes were blocked in a 5% milk in PBS-
Tween20. Specific antibodies for both SPARC (R & D Systems, Minneapolis, MN) and β-
Actin (Santa Cruz Biotechnology, Santa Cruz, CA) were used to detect protein levels, 
which were quantified using chemiluminescence on a Fuji gel documentation system 
(Fujifilm Life Sciences, Stamford, CT). 
 
Hydroxyproline Assay: Quantitation of lung collagen content from exposed and control 
mice was determined by an assay for hydroxyproline content according to methods 
previously described (Woessner, 1961) with some modifications. The caudal lobe of the 
left lung was rinsed in PBS, minced and hydrolyzed in 1.5ml of 6N HCl overnight at 
110°C. To 5µl of the hydrolysate were added 10µl of 0.02% methyl red and 2µl of 
0.04% bromothymol blue. Sample volume was adjusted to 200µl with assay buffer 
(0.024M Citric Acid, 0.02M Glacial Acetic Acid, 0.088M Sodium Acetate, and 0.085M 
NaOH). The colorimetric assay was performed by the addition of 100µl of chloramine T 
solution and incubation at room temperature for 20 minutes. Following incubation, 100µl 
of dimethyl benzaldehyde solution was added and the solution incubated in a 60°C 
water bath for 15 minutes. Absorbance was measured at 550nM for each lung sample in 
a 96-well plate and quantitation of hydroxyproline was determined by comparison to a 
standard curve.  
 
Statistical Analysis: Mean values for the hydroxyproline and Sircol assays were compared 
by one-way ANOVA with a Newman-Keuls test for multiple comparisons. Results are 
presented as mean values ± SEM. Densitometry values taken from replicate samples run 
on Western blots were normalized to β-Actin, then asbestos treated samples were 
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analyzed for percent expression versus the PBS treatment group. A one-way ANOVA 
with a Newman-Keuls test for multiple comparisons was used to verify the significance 
of the mean percent expression values and results are presented as mean values ± SEM 
versus PBS. Significant results were determined by p < 0.05. 
 
Results 
 
 Lentivirus, a retrovirus commonly utilized as a gene delivery vector, was used to 
transduce cells with small interfering RNA (siRNA) directed against SPARC. These viruses 
have the ability to deliver genetic information directly into the nucleus of the host cell. 
The siRNA then are integrated into the host’s DNA. The small hairpin RNA (shRNA) 
lentiviral vectors I used to inhibit Sparc expression were packaged into the pLKO.1-puro 
plasmid (Figure 21). This plasmid is capable of establishing either stable or transient 
transductions of shRNA as well as lentiviral particle production. pLKO.1-puro is especially 
useful when attempting long-term knockdown in sensitive cell lines such as primary 
cells. The sequences used for the shRNA inserts into the vectors can be found in Table 4 
and the viruses containing these inserts will be referred to by the last three digits of the 
MISSION TRC No (Table 4 in blue).  
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Figure 21: MISSION RNAi pLKO.1-puro Vector Map 
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Figure 21 Legend: This vector map of the Sigma-Aldrich MISSION RNAi pLKO.1-puro 
plasmid was provided by Sigma-Aldrich at http://www.sigmaaldrich.com/life-
science/functional-genomics-and-rnai/shrna/library-information/vector-map.html. The 
sequences of the SPARC shRNA strands can be found in Table 4. 
 139 
Table 4: SPARC shRNA Target Sequences 
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 After each virus was made, the titer was verified following the manufacturer’s 
protocols utilizing the puromycin resistance gene contained in the vector. The Non-
Target (NT) Control contains 4 base pair mismatches within the short hairpin sequence 
to any known human or mouse genes and can therefore be used as a negative control. 
The GFP control contains TurboGFP, a variant of the green fluorescent protein copGFP, 
in place of shRNA and can therefore be used as a positive control to monitor 
transduction efficiency. The determined titers are listed in Table 5. Cells were infected 
with a serial dilution of titered units of each virus (Table 5), to determine the multiplicity 
of infection (MOI). The MOI was verified in order to determine the viral particle number 
of each virus. Next the knockdown ability of each virus was assayed by western blotting 
(Figure 22E). This would allow for selection of the proper virus for both the in vitro and 
in vivo portions of the study. The viruses were found to have the following maximum 
SPARC knockdown abilities: 349-50% (Figure 22A), 350-63% (Figure 22B), 351-38% 
(Figure 22C), and 352-36% (Figure 22D). From these results, virus 350 was used for in 
vitro studies and 352 for in vivo studies. Virus 352 was chosen for in vivo studies even 
though it had the least amount of SPARC knockdown because it had the highest titer 
and I could therefore instill more titered units into the mice without fear of them 
drowning, an adverse event that can occur during instillation. In order to enable the 
instillation of even more titered units (TU) in vivo, virus 352 was concentrated following 
the manufaturer’s instructions. The final concentrated titer for virus 352 was 5 x 106 
TU/ml. 
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Table 5: Lentivirus Titers 
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Figure 22: SPARC siRNA Virus Knockdown Ability 
 
A. B. 
C. D. 
E. 
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Figure 22 Legend: Primary mouse lung fibroblasts at 60% confluence were grown in 6-
well plates and treated with equal titered units of one of four viruses containing siRNA 
directed against SPARC: 349, 350, 351, and 352. After 24 hours the viruses were 
removed and cells cultured for another 24 hours in complete media. The titered units 
used for each sample are listed on Table 5. Protein was harvested at the completion of 
the final incubation and analyzed by immunoblotting to determine the percent 
expression versus no virus treatment. Results are presented as percent expression 
versus a no virus control. All four viruses had decreases in SPARC protein expression 
ranging from 63% to 36%. 
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Primary mouse fibroblasts were isolated from the lungs of WT C57Bl/6 mice and 
cultured for in vitro analysis (Migliaccio, 2005). Cells were then exposed to 5µg/cm2 of 
crocidolite (CRO) asbestos for 6, 12, or 24 hours. Initially, immunocytochemistry (ICC) 
was performed to visually determine if there were any differences in SPARC expression. 
ICC is also a useful tool to identify the cellular location of SPARC expression with or 
without asbestos treatment. After 6 hours of asbestos treatment, the CRO treated 
fibroblasts appeared to have higher SPARC expression than PBS treated cells (Figure 
23). Transduction of either the NT control virus or virus 350 did not appear to change 
this. This trend continued at both 12 hours (Figure 24) and 24 hours (Figure 25) of 
asbestos exposure. However, it was difficult to find an area to image on slides covered 
in cells treated with both CRO and virus 350. Those cell clusters that stained for SPARC 
may not have received the virus. To be sure, western blotting is needed to quantify 
SPARC protein expression. No differences were seen over time. It is also interesting to 
note that it appears as though SPARC is localized to the cytoplasm until exposed to 
asbestos where it may be moving into the nucleus or localizing to the nuclear 
membrane. Confocal microscopy along with markers for nuclear membrane bound 
protein could be used to verify this. 
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Figure 23: 6 Hour SPARC Immunocytochemistry 
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Figure 23 Legend: Primary mouse lung fibroblasts were plated at equal density on sterile 
coverslips in complete medium. Once they were approximately 50% confluent, CRO was 
added to the media. 6 hours later the asbestos containing media were removed, the 
cells quickly rinsed with sterile PBS and complete media containing either no virus (NV), 
a Non-Target virus (-CNT), or virus 350 was added. 24 hours post transduction, the 
virus containing media were removed and replaced with complete media for another 24 
hours before the cells were fixed for detection of SPARC by immunostaining. Images are 
200x. 
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Figure 24: 12 Hour SPARC Immunocytochemistry 
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Figure 24 Legend: Primary mouse lung fibroblasts were plated at equal density on sterile 
coverslips in complete medium. Once they were approximately 50% confluent, CRO was 
added to the media. 12 hours later the asbestos containing media were removed, the 
cells quickly rinsed with sterile PBS and complete media containing either no virus (NV), 
a Non-Target virus (-CNT), or virus 350 was added. 24 hours post transduction, the 
virus media was removed and replaced with complete media for another 24 hours 
before the cells were fixed for immunostaining with antibodies directed against SPARC. 
Images are 200x. 
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Figure 25: 24 Hour SPARC Immunocytochemistry 
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Figure 25 Legend: Primary mouse lung fibroblasts were plated at equal density on sterile 
coverslips in complete medium. Once they were approximately 50% confluent, CRO was 
added to the media. 24 hours later the asbestos containing media were removed, the 
cells quickly rinsed with sterile PBS and complete media containing either no virus (NV), 
a Non-Target virus (-CNT), or virus 350. 24 hours post transduction, the virus media 
was removed and replaced with complete media for another 24 hours before the cells 
were fixed for detection of SPARC by immunostaining. Images are 200x. 
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To verify if there were any quantifiable differences in SPARC expression in the 
treated fibroblasts, western blotting was performed on protein isolated from treated cells 
(Figure 26). The cells exposed to PBS alone (No virus – NV) or PBS in addition to –CNT 
virus or virus 350 show no significant differences in SPARC expression (Figure 26A). 
Compared to the NV and –CNT virus treatment groups, the cells treated with virus 350 
show significant decreases in SPARC protein after CRO exposure but not after PBS 
exposure (Figures 26A and 26B). The virus was successful at reducing SPARC expression 
when determining the MOI (Figure 22) but was not successful at reducing the level of 
SPARC in cells treated with both virus 350 and PBS. This is most likely a result of the 
PBS treated cells in this experiment being too confluent at the time of virus transduction. 
Because these PBS treated cells were not replicating, the siRNA may not have 
incorporated into host DNA as efficiently as in the cells treated with CRO. 
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Figure 26: In Vitro SPARC siRNA Virus PBS and CRO Western Blots 
 
 
A. 
B. 
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Figure 26 Legend: Primary mouse fibroblasts were plated at equal densities in T25 flasks 
and treated as described in Figure Legends 23-25. Upon treatment completion, protein 
was harvested, quantified, and run in equal amounts on western blots to determine 
SPARC protein expression. Results are presented as mean percent expression vs. 6Hr NV 
PBS ± SEM. No significant differences were detected in PBS treated cells at any time 
point (A). At all three time points there is significantly less SPARC protein in the 350 
virus exposed cells than either NV or -CNT exposed cells after CRO treatment (B). Also 
there is significantly less SPARC expression in the cells exposed to both virus 350 and 
CRO at every time point compared to the cells exposed to no virus and PBS for 6 hours 
(B). * = p < 0.05, ** = p < 0.01, *** = p < 0.001 
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Changes in each viral treatment group were also analyzed to determine 
differences over time and between PBS and CRO exposure (Figure 27). When comparing 
cells infected with NV, those cells exposed to CRO versus those exposed to PBS show no 
differences in SPARC expression (Figure 27A). Though it does appear as though there is 
a slight increase in expression in the CRO treated  cells at 24 hours when compared to 
PBS, and there is a significant increase in SPARC expression in the CRO treatment group 
from 6 to 24 hours. The results of SPARC expression analysis in the –CNT viral group 
directly mimic those of the NV viral group with the only significant difference being the 
increase in expression in the CRO treatment group from 6 to 24 hours (Figure 27B). The 
cells in the 350 virus treatment group have significantly less SPARC expression in CRO 
treated fibroblasts than PBS treated fibroblasts at every time point (Figure 27C). Again, 
this could be due to the PBS treated cells being too confluent at the time of virus 
transduction. No significant differences in the virus 350 exposure group were detected 
over time. Overall, treatment with the virus containing siRNA directed against SPARC 
was capable of significantly decreasing SPARC expression after CRO exposure. 
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Figure 27: In Vitro SPARC siRNA Virus, -CNT Virus, and No Virus Western Blot 
 
A. 
B. 
C. 
** 
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Figure 27 Legend: The data presented in Figure 26 was re-analyzed to compare PBS 
treatment to CRO treatment and to compare SPARC expression levels over time. Results 
are again presented as mean percent expression vs. 6Hr NV PBS ± SEM. In both the NV 
(A) and –CNT (B) groups exposed to CRO showed a significant increase in SPARC 
protein from 6 to 24 hours but no significant differences when comparing CRO exposure 
to PBS exposure. The 350 Virus treatment groups showed a significant decrease in 
SPARC expression after CRO treatment compared to PBS treatment (C). * = p < 0.05, 
** = p < 0.01, *** = p < 0.001  
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The Sircol Assay was used to determine if the decreased SPARC protein 
expression in CRO exposed fibroblasts transduced with virus 350 has any effect on 
collagen deposition (Figure 28). The Sircol Assay is a quantitative method for the 
analysis of acid-soluble collagens both in vivo and in vitro. It is capable of measuring 
mammalian types I to IV collagen. Mouse primary lung fibroblasts were exposed to 
either PBS or CRO for 6, 12, or 24 hours and then to either a no-virus control (NV), non-
target control (-CNT), or virus 350 (VIRUS) containing the siRNA directed against SPARC 
for 24 hours. Analysis of both the 6 hour and 12 hour exposure time points revealed no 
significant differences between cells exposed to PBS and cells exposed to CRO, though it 
appeared as if cells treated with CRO had slightly more collagen than their PBS treated 
counterparts in both NV and -CNT treated controls (Figures 28A and 28B). It also 
appeared as though cells treated with both CRO and virus 350 had less collagen content 
than either of the CRO treated viral control cells at both the 6 hour and 12 hour time 
points, however, the difference was again not significant. At 24 hours of exposure, an 
increase in collagen was seen in CRO exposed cells treated with either the NV or –CNT 
controls compared to their PBS exposed counterparts, this increase being significant in 
the –CNT treatment group (Figure 28C). No such increase was seen in the cells exposed 
to both CRO and virus 350 compared to their PBS exposed counterparts. In addition, a 
significant decrease was found in the cells exposed to both CRO and virus 350 compared 
to those exposed to CRO and the non-target control. At 24 hours of exposure, the siRNA 
directed against SPARC induced a significant decrease in collagen deposition in wild-type 
mouse lung fibroblasts. 
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Figure 28: In Vitro SPARC siRNA Virus Sircol Assay 
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Figure 28 Legend: Primary mouse fibroblasts were plated at equal densities in 6-well 
plates and treated as described in Figure Legends 23-25. Upon treatment completion, 
cells were harvested with cell scrapers and total collagen content was quantified with 
the Sircol Assay. This value was normalized against the total protein concentration and 
results are presented at the mean percentage of collagen in the total protein ± SEM. No 
significant changes were detected at either 6 (A) or 12 (B) hours of CRO/PBS exposure. 
At 24 hours of CRO or PBS exposure (C), the cells exposed to the non-target control 
virus (-CNT) had significantly more collagen content if they were also treated with CRO 
than if they were treated with PBS. Furthermore, the cells treated both CRO and the –
CNT virus had significantly more collagen content than the cells treated with both CRO 
and virus 350. 
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As a preliminary study with limited available mice, I next used WT C57Bl/6 mice 
who had already been exposed to CRO asbestos for two months to determine if siRNA 
directed against SPARC could also decrease SPARC expression in vivo and help to reduce 
some of the excess collagen deposited during the development of asbestosis. Virus 350 
was intratracheally instilled after the two month asbestos exposure time and mice were 
sacrificed one month following virus instillation. Therefore, total asbestos exposure time 
was three months at the completion of the experiment. Unfortunately the negative non-
target control virus was not ready when the mice were, so the GFP lentivirus was used 
instead as a control. This portion of experiments should be repeated using the –CNT 
virus.  
Western blotting for SPARC protein revealed no significant differences between 
the GFP control group, media vehicle control group, or 352 Virus group (Figure 29). It 
does appear as though the mice exposed to CRO have slightly more SPARC than the PBS 
exposed mice in both the GFP and Media control groups, but the difference is not 
significant. This mimics the results seen in the previous 3 month WT study (Chapter 2) 
presented in Figure 13. SPARC was no longer suppressed at the completion of the 
incubation period; however, this may be because not enough virus was introduced into 
the lung to induce a detectable decrease in SPARC expression. However, collagen 
deposition could still have been altered if some of the SPARC present in the lung was 
silenced.  
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Figure 29: In Vivo SPARC siRNA Virus Western Blot 
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Figure 29 Legend: Immunoblotting of SPARC protein from the lungs of C57Bl/6 mice 
exposed to PBS or CRO for two months followed by GFP virus, virus 352, or media as a 
vehicle control for an additional month. Results for each treatment group (n = 5 – 8 per 
group) were normalized to β-actin and are presented as the mean percent expression 
versus GFP PBS ± SEM. No significant differences in SPARC protein expression were 
found. 
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Histological examination revealed that collagen deposition around the airways 
was increased in the crocidolite treated animals (collagen appears blue-green in Gomori 
Trichrome-stained sections, indicated by the arrows, Figure 30D, 30E, and 30F), which 
represented the typical pattern of fibrosis seen in animals exposed to crocidolite. Multi-
nucleated giant cells and activated macrophages are also apparent in the CRO-exposed 
animals which resembles what was previously found for three month treated wild type 
mice (Figure 16), a further indication of the chronic inflammation and fibrosis. PBS 
treated mice did not show signs of excessive collagen deposition or inflammation which 
is also similar to the results previously presented for 3 month wild-type mice (Figure 
30A, 30B, and 30C). Instillation of GFP control virus (GFP), no-virus (NV) or virus 352 
did not appear to significantly alter the level of collagen deposition. However, it does 
appear that mice instilled with both CRO and virus 350 (Figure 30F) had a decreased 
level of collagen accumulation in comparison to the mice exposed to both CRO and GFP 
(Figure 30D) or CRO and NV (Figure 30F). In order to verify this, total collagen content 
of the lungs must be verified. 
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Figure 30: In Vivo SPARC siRNA Virus Histology 
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Figure 30 Legend: Gomori Trichrome-stained 7 µM sections of mouse lungs from 
C57Bl/6 WT mice instilled with CRO or PBS for two months followed by treatment with 
either GFP virus (GFP), no-virus (NV), or virus 352 for one additional month (200X 
original magnification).  Blue-green staining indicates collagen deposition and arrows 
point to areas of increased accumulation. In every viral treatment group (GFP, NV, and 
352), the airways of the amphibole exposed mice showed much higher levels of collagen 
accumulation and inflammation than PBS exposed mice. It does appear, however, that 
the level of collagen accumulation in the mice treated with both CRO and virus 350 (F) 
was less than that of the mice treated with CRO and either NV (E) or GFP (D). 
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The hydroxyproline assay was used to quantify total collagen content in the 
lungs of treated mice in order to determine if the SPARC siRNA virus had any effect on 
alleviating collagen deposition after animals had already been exposed to asbestos and 
developed fibrosis. No significant differences were found in total hydroxyproline between 
CRO and PBS exposed mice in either the GFP control group or the 350 virus group 
(Figure 31A). The media control group had significantly more hydroxyproline after CRO 
exposure than after PBS exposure. To analyze how this result compared to the previous 
results presented in Chapter 2 for the 3 month treated WT mice, the results were 
basically identical (Figure 31B). This indicates how consistent and reliable this assay is to 
determine total collagen. Even though there was no detectable decrease in SPARC 
protein expression in the mice exposed to the virus containing siRNA directed against 
SPARC, the virus was able to reduce collagen levels back to PBS baselines.  
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Figure 31: In Vivo SPARC siRNA Virus Hydroxyproline Assay 
 
A. 
B. 
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Figure 31 Legend: Total hydroxyproline content was determined from the lungs of 
C57Bl/6 mice exposed to PBS or CRO for two months followed by GFP virus, virus 352, 
or media as a vehicle control for an additional month. Collagen content was determined 
by measuring hydroxyproline levels in replicate animals. All experiments were done in 
triplicate. Results are presented as mean values ± SEM for each treatment/time (all 
groups have n = 4 - 5). Only the CRO exposed Media control group had significantly 
more hydroxyproline than the PBS exposed counterparts (A). There was also a 
significant decrease in the amount of hydroxyproline present in the lungs of CRO 
exposed 350 virus mice compared to the CRO exposed Media control mice. When 
comparing the data found for both the PBS and CRO exposed media control groups with 
the previously presented WT 3 month data from Figure 10, the results appear to be 
nearly identical (B). * = p<0.05, ** = p<0.01, *** = p<0.001.  
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Discussion 
 
 Fibroblasts are activated in fibrotic disorders where they are stimulated to 
produce extracellular matrix components such as collagens (Claman, 1991). The 
biosynthesis and deposition of these components are regulated by matricellular proteins 
and growth factors (Varedi, 1997). One such matricellular protein with the ability to 
regulate collagen deposition in fibrotic disorders is SPARC. It remains to be seen, 
however, if the reduction of SPARC in individuals already suffering from fibrosis can halt 
or even reverse the excess collagen accumulation.  
The utilization of RNA interference for gene silencing and knockdown is common. 
It is an efficient method to facilitate the degradation of target mRNA and thus achieve 
the resulting gene silencing (Wall, 2003). The use of this technology has already been 
suggested for use therapeutically on genes like the tumor suppressor p53 and the Ras 
oncogene (Dykxhoorn, 2003). In this study I used RNAi to silence SPARC expression 
both in vitro and in vivo after asbestos exposure to evaluate the effect of the silencing 
on collagen accumulation. 
In primary mouse fibroblasts isolated from the lungs of wild-type C57Bl/6 mice, 
lentiviral vector delivered SPARC siRNA was successful in reducing SPARC protein 
expression up to 63%. Once the cells were exposed to CRO asbestos, SPARC expression 
was slightly increased though not significantly so when compared to PBS. Transduction 
of the CRO exposed fibroblasts with SPARC siRNA virus caused a significant decrease in 
SPARC expression, though PBS exposed cells that were also transduced with the siRNA 
virus did not show a decrease in SPARC expression. The reduction of SPARC expression 
in the CRO treated cells resulted in less collagen accumulation, especially after 24 hours 
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of exposure, which is similar to a previous investigation where it was reported that the 
use of SPARC siRNA was associated with a decrease in type I collagen levels in human 
fibroblasts (Zhou, 2005). 
The lack of a reduction in SPARC expression in the PBS treatment group was 
most likely due to the higher confluency of the PBS treated cells which may have 
hindered the ability of the siRNA plasmid to incorporate into the host DNA. It was 
apparent that cells exposed to CRO were much less viable than cells exposed to PBS for 
the experiment duration. Fibroblasts exposed to CRO were approximately 50% confluent 
at the completion of the experiment whereas the PBS exposed fibroblasts were almost 
fully confluent. The PBS treated cells were therefore no longer dividing as much as the 
CRO treated cells when the virus was administered. If the lentivirus did not incorporate 
effectively into the DNA of dividing cells, I would hypothesize that little virus made it into 
the PBS treated fibroblasts, which would result in less siRNA production and 
subsequently less SPARC knockdown.  
Due to the ability of SPARC siRNA to decrease the expression of both SPARC and 
collagen in vitro, I decided to use the lentivirus in vivo after mice had already developed 
fibrosis. This would demonstrate the ability of SPARC siRNA to be used therapeutically in 
individuals with existing fibrotic conditions. Initially, it appeared that administration of 
the SPARC siRNA lentivirus to wild-type mice suffering from asbestos-induced fibrosis 
did not significantly decrease SPARC expression in the lung. However, CRO exposed 
mice who also received siRNA virus appeared to have less collagen accumulation than 
the mice exposed to both CRO and the GFP control virus or CRO and no-virus. This 
decrease in collagen deposition seen histologically was found to be significant after 
quantification of total lung collagen. This indicates that waiting a month after virus 
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application for sacrifice may have been too long to see the effects of the virus on SPARC 
expression. Regardless the siRNA was capable of not only halting collagen deposition 
but also reducing the already present levels back to baseline. The mechanism by which 
SPARC could be responsible for this reduction warrants further study. 
The fibrotic mice instilled with the GFP lentivirus did not show the same 
significant increase in total collagen as the media vehicle control fibrotic mice. This may 
indicate that the significant decrease in collagen in the siRNA virus instilled animals was 
not a result of the SPARC siRNA but maybe an artifact of the viral vector. In order to 
confirm the results seen here, collagen content should be quantified from fibrotic mice 
instilled with the non-target (NT) negative control virus. This virus was not ready for use 
in the in vivo study when the mice were ready. Once the ability of SPARC siRNA to 
reduce collagen deposition in the fibrotic lung has been confirmed, it may be developed 
into a potential therapeutic agent for the treatment of not only pulmonary fibrosis but 
other fibrotic diseases as well. 
 
Conclusion 
 
 Millions of people currently suffer from pulmonary fibrosis without any hopes of 
cure. It is already known that a complete lack of SPARC in mice treated with asbestos or 
bleomycin as a fibrosis-inducing agent decreases the amount of collagen accumulation 
in the lung. Here I show that the use of RNA interference to silence SPARC expression in 
mice already suffering from pulmonary fibrosis may have the ability to reverse collagen 
deposition in the lung. With more research, silencing SPARC with siRNA could be used as 
therapy to treat the millions of people suffering from fibrotic diseases. 
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SUMMARY 
 
 Pulmonary fibrosis is a serious medical condition with no cure. It is caused by a 
variety of environmental and pharmaceutical agents. Here I used asbestos-induced 
fibrosis as a model to study the ability of SPARC to regulate collagen accumulation in a 
fibrotic lung. The matricellular protein SPARC had previously been implicated as a 
regulator of collagen accumulation in bleomycin-induced fibrosis. Expression of SPARC, a 
regulator of cell-matrix interactions, was also found to be upregulated in a fibrotic lung 
after both one year and six months of asbestos exposure and therefore was a candidate 
for further study. 
 Here I show that both collagen accumulation and SPARC expression are 
increased in a wild-type mouse lung using a short-term asbestos exposure to induce 
fibrosis. To confirm whether or not these observations were correlated, fibrosis was 
induced through asbestos exposure in SPARC-null mice. The SPARC-null mice exposed 
to asbestos did not show the significant increase in collagen deposition as the wild-type 
fibrotic mice did. These results corresponded with some previous investigations into 
bleomycin-induced models of pulmonary fibrosis by further demonstrating the ability of 
SPARC to regulate the collagen deposition and subsequent scar tissue formation in the 
lung. Therefore SPARC may be a potential therapeutic target in the treatment of many 
fibrotic diseases, aside from asbestosis and bleomycin-induced pulmonary fibrosis. A 
model of asbestos-induced pulmonary fibrosis including the role of SPARC as discovered 
throughout this project in collagen deposition can be found in Figure 32 (red arrows). 
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Figure 32: The Role of SPARC in Asbestos-Induced Pulmonary Fibrosis 
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Figure 32 Legend: A model of asbestos-induced fibrotic disease. Blue arrows represent 
previously known routes of disease formation that include both inflammation and scar 
tissue formation. Briefly, after asbestos exposure to the lung, fibroblasts are stimulated 
by growth factors to deposit collagen around the foreign fibers and leukocytes, like 
macrophages, are stimulated to eradicate the foreign matter. However, due to the 
natural resistance of asbestos to phagocytic activity, the macrophages begin to die at 
which point they release cytokines to both recruit new macrophages to the area and 
stimulate fibroblasts to lay down more collagen. This perpetual stimulation of both the 
immune system and collagen deposition lead to the inflammation and scar tissue 
formation commonly associated with fibrosis. The red arrows represent the additional 
role of SPARC in this process as found in this dissertation project. I have found that the 
expression of SPARC is increased in fibroblasts after asbestos exposure (Chapter 3). This 
increase in expression leads to a significant increase in collagen deposition in the lung 
(Chapters 1 and 2). 
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 To explore the therapeutic potential of SPARC knockdown, I used siRNA directed 
against SPARC mRNA to silence SPARC expression in a model of fibrosis both in vitro 
and in vivo. Primary mouse lung fibroblasts exposed to asbestos showed an increase in 
collagen levels at 24 hours post-exposure that was mitigated after transduction of the 
cells with a virus containing the SPARC siRNA. These results resembled what was seen 
in vivo, where fibrotic mice instilled with the siRNA containing virus had significantly less 
collagen accumulation than the fibrotic mice that did not receive the virus. Though the 
results of this portion of the project are inconclusive until more experiments can be 
performed, it appears that the silencing of SPARC expression in individuals already 
suffering from fibrosis may have significant therapeutic potential. 
 There are several directions with which to take the results presented here in the 
future. Primarily, more research needs to be performed with the SPARC siRNA 
containing virus in vivo.  The three month experiment should be repeated using a non-
target negative control instead of the GFP control to determine if the decrease seen in 
collagen deposition was a result of the siRNA or a response to the presence of the viral 
vector. Also, the viral incubation period should be shortened in order to detect a 
reduction in SPARC expression. A similar experiment could be designed for a one month 
time point as well, because the disease in mice appears to be the most severe at this 
time and a one month study would complement the three month data.  
 It is also necessary to study the pathways by which SPARC may be inducing 
collagen synthesis and deposition. Specifically, the involvement of SPARC in the TGF-β 
signaling pathways of JNK and SMAD2/3 should be evaluated in an asbestos-induced 
model of fibrosis. I attempted to evaluate protein expression changes in the SMAD2/3 
pathway in mice exposed to asbestos but was unsuccessful in getting a phosphorylated 
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SMAD antibody to work. Analysis of these pathways as well as the interactions between 
SPARC and TGF-β would both confirm previous studies and provide more insight into the 
mechanism by which SPARC contributes to fibrosis development in the lung. 
 In terms of in vitro studies, it would be interesting to use primary lung fibroblasts 
from SPARC-null mice to study not only the influence of SPARC on collagen expression 
but also how SPARC influences the expression of other genes involved in the fibrotic 
response. This would be useful to determine more specifically the mechanism by which 
SPARC functions in fibroblasts during the development of pulmonary fibrosis. The results 
from such a study could provide more potential therapeutic targets for the treatment of 
fibrotic diseases. It would also be beneficial to determine if SPARC was localizing to the 
nucleus in vitro after CRO exposure with nuclear staining. If it is, more insight could be 
gained as to why SPARC is moving into the nucleus and what the subsequent effects are 
in both the cell and extracellular space.  
More in vitro studies could be performed using co-cultures of fibroblasts and 
epithelial cells. As the role of SPARC in the fibrotic response involves mainly fibroblast 
and epithelial cells, a co-culture experiment would provide results that may more 
resemble those seen in vivo. A co-culture study would also yield more information 
regarding the mechanism of action of SPARC as well as the interaction between the two 
cell types. Furthermore, if the in vivo response could be replicated more closely in vitro, 
it would be both cost efficient and time saving. 
It has been suggested that the protein Hevin compensates for the lack of SPARC 
in SPARC-null mice. Though there were significant decreases in collagen accumulation in 
SP-null mice, there were some significant increases seen in type III collagen mRNA. This 
may indicate that another protein, like Hevin, could be compensating for SPARC in the 
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SP-null mice. Therefore, fibrosis studies should be carried out in SPARC/Hevin double-
null mice. Results from such a study would confirm if Hevin is in fact compensating for 
SPARC and may also provide some insight into the similarities between the two genes 
when compared with results from studies in SP-null mice. 
 Finally the in vivo studies utilizing the SPARC-null mice could be repeated with 
the addition of an immunosuppressant. The SP-null mice exposed to asbestos showed 
significantly less collagen deposition in the lungs but no change in the inflammatory 
response. Silencing of SPARC only addresses half of the fibrotic response. To truly help 
individuals suffering from fibrosis, it must be dealt with on two fronts. Both the level of 
collagen production must be reduced and the inflammatory response must be 
modulated. If it is possible to accomplish both of these tasks, a cure for fibrosis may be 
developed in the near future. 
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APPENDIX A: Elutriated Libby Amphibole 
 
 The type of amphibole found in the vermiculite mines in Libby is unlike all the 
other well-studied forms of amphibole asbestos for several reasons. One is the varied 
composition of the Libby amphibole fibers, which include a variety of fiber types 
including tremolite, winchite, and richterite (Meeker, 2003). Another is a difference in 
the chemical composition of the fibers, where the various fibers that compose Libby 
asbestos all have different proportions of cations like Mg, Ca, Fe, Na, and K (Webber, 
2008). Additionally, varied fiber sizes that differ from other well-studied forms of 
asbestos may cause a different response. 
 Fiber size plays a significant role in disease development after asbestos 
exposure. Early studies indicated that fibers greater than 8µm in length are more 
pathogenic than the shorter fibers (Mossman, 1989) and are more likely to cause 
mesothelioma (Stanton, 1981). However, more recent studies have suggested that both 
long and short fibers are equally capable of causing a response (Dodson, 2003; Suzuki, 
2005). In fact, it has been hypothesized that after exposure to amphibole similar to 
those from Libby where there is a mixed fiber size (Meeker, 2003), the longer fibers get 
trapped in the upper airways where they are removed by mucociliary factors 
(Shusterman, 2003), and therefore the smaller, respirable fibers are the ones that can 
travel down to the alveoli at the lung bases. If this is correct, the shorter fibers would be 
more capable of causing disease in vivo.  
 In order to examine this hypothesis, I was able to utilize Libby amphibole fibers 
with lengths less than 2.5µm after an elutriation technique was perfomed (Webber, 
2008). Dr. Tony Ward at the University of Montana provided the elutriated Libby 
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amphibole fibers (E.LA) for this study. There were no apparent differences in the 
chemical composition between the E.LA and the normal LA (Webber, 2008). As was 
previously described in Chapters 1, 2, and 3, C57Bl/6 WT and SP-null mice were 
intratracheally instilled with 100µg of the elutriated LA fibers suspended in 30µl PBS or 
PBS alone as a vehicle control. The mouse lungs were harvested after one month and 
three month exposures for analysis. The lungs were divided for histological analysis, 
RNA isolation, protein isolation, and the hydroxyproline assay. Histology along with RNA 
and protein analysis will not be presented here. 
 Hydroxyproline content is a surrogate measure for total collagen. Both WT and 
SP-null lungs were analyzed for total hydroxyproline after one month or three month of 
exposure to elutriated LA (Figure 33). After both one month (Figure 33A) and three 
months (Figure 33B) there was a significant increase the level of total hydroxyproline in 
the lungs of mice exposed to the elutriated Libby amphibole compared to PBS treated 
controls. As was seen in Chapter 2, lack of SPARC in the mice (SP-null) significantly 
mitigated this effect. 
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Figure 33: Elutriated LA Hydroxyproline Assay 
 
A. 
B. 
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Figure 33 Legend: Total hydroxyproline content from the lungs of WT and SP-null mice 
exposed to PBS or E.LA. Mice were intratracheally instilled for 1 or 3 months and 
collagen content of the left lung was determined by measuring hydroxyproline levels in 
replicate animals. All experiments were done in triplicate. Results are presented as mean 
values ± SEM for each treatment/time (all groups have n = 6-10). Lungs from both the 
one month and three month E.LA exposed WT mice have significantly more 
hydroxyproline than the PBS controls. Hydroxyproline levels of lungs from E.LA exposed 
SP-null mice are no different than their PBS exposed counterparts. (* = p < 0.05, ** = 
p < 0.01, *** = p < 0.001).  
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I also analyzed the new E.LA hydroxyproline data against the previous normal LA 
data presented in Chapters 1 and 2 (Figure 34). At the one month time point, lungs 
from mice exposed to both E.LA and normal LA demonstrated a significant increase in 
hydroxyproline content compared to PBS treated lungs (Figure 34A). There was, 
however, no difference between the hydroxyproline between E.LA and LA treated lungs. 
By three months post-exposure, both the LA and E.LA treated lungs contained 
significantly higher amounts of hydroxyproline compared to PBS treated controls. In 
addition, at three months after asbestos exposure, the E.LA treated WT lungs also 
contained significantly more hydroxyproline than the LA treated WT lungs (Figure 34B). 
This could be an indication that the shorter, elutriated LA fibers cause higher levels of 
collagen accumulation over time.  
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Figure 34: Normal vs. Elutriated LA Hydroxyproline Assay 
 
A. 
B. 
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Figure 34 Legend: Total hydroxyproline content from the lungs of WT and SP-null mice 
exposed to PBS, normal LA, or E.LA. Experiments were perfomed as was previously 
described in the legend for Figure 31. When compared to the WT normal LA instilled 
mice, the WT mice instilled with elutriated LA have significantly more hydroxyproline at 
three months after exposure. (* = p < 0.05, ** = p < 0.01, *** = p < 0.001). 
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Conclusion: 
 
No significant differences in total hydroxyproline between the normal LA and 
E.LA treated lungs were seen until three months post-exposure. However, it may be that 
the shorter fibers are more hazardous in the long run. It is thought that exposure to 
fibers of different lenghths can cause different asbestos-related diseases (Lippman, 
1990). Based on the outcome that shorter fibers caused increased collagen deposition at 
three months, it is possible that inhalation of these respirable fibers may cause more of 
a fibrotic disease than a cancerous one. However, this is only one experiment and much 
more research into this issue must be done in the future to fully understand the 
differences in pathogenicity between the various fiber lengths. 
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APPENDIX B: Hevin 
 
 Hevin (also known as SC1, MAST 9, SPARC-like 1, or ECM 2) is a member of the 
SPARC family that also includes QR1, the testicans and the SMOCs (Vannahme, 2002). 
Like SPARC, the protein consists of three domains: acidic, follistatin-like, and 
extracellular calcium-binding (Hambrock, 2003). The last two domains closely resemble 
those found in SPARC, however the acidic domain has not been found to resemble any 
other protein. Furthermore, like SPARC, Hevin functions in inhibiting cell adhesion 
(Bradshaw, 2001), inhibiting cell attachment and spreading (Girard, 1996), and may play 
a role in cancer as a negative regulator of cell proliferation and growth (Nelson, 1998; 
Bendik, 1998; Claeskens, 2000). The ability of Hevin to modulate cell-matrix interactions 
is still under investigation. Regardless, it has been shown that tumors grown in SP-null 
mice do not present with expected increases in cell proliferation and angiogenesis. 
(Brekken, 2003).  
Based on the similarity in the functioning of both SPARC and Hevin, it has been 
hypothesized that Hevin may play a compensatory role for SPARC in SP-null mice. To 
examine this hypothesis, I analyzed both Hevin mRNA and protein levels in SP-null mice 
exposed to asbestos to see if levels increased in an attempt to compensate for the lack 
of SPARC. I utilized the same mice instilled for the data presented in chapters 1 and 2. 
Again, the RNA and protein were isolated in the manner described in previous chapters 
and analyzed for Hevin expression. Determining the ability of Hevin to compensate for 
SPARC in a fibrosis model may help to identify the role of Hevin in cell-matrix 
interactions.  
 First I examined the levels of Hevin mRNA via quantative Real-Time PCR to 
determine if there were any expression alterations in either WT or SP-null mice exposed 
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to asbestos (Figures 35 and 36). There were no significant differences in Hevin 
expression detected in WT mice at any of the three time points analyzed for any 
exposure group (Figure 35A). There were, however, significant decreases in Hevin 
mRNA levels in lungs from SP-null mice exposed to LA at both the one week and three 
month time points (Figure 35B). When comparing the levels of Hevin mRNA expression 
between WT and SP-null mice, no differences were found for either the CRO treatment 
group (Figure 36A) or the LA treatment group (Figure 36B). In terms of mRNA 
expression, it does not appear that more Hevin mRNA is synthesized to compensate for 
SPARC in SP-null mice. 
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Figure 35: Hevin qRT-PCR 
 
A. 
B. 
 193 
Figure 35 Legend: Real-Time PCR of Hevin mRNA from the lungs of either C57Bl/6 WT 
or SP-null mice treated with PBS, CRO, or LA. Each experiment was repeated three 
times.  Results from triplicate pools of RNA for each treatment group (n = 10 – 12 per 
group) were normalized to both Gapdh and β-actin and are presented as mean fold 
difference ± SEM. The only significant differences in Hevin mRNA expression occur at 
one week and three month in the LA treatment group when compared to the PBS 
treatment group. When each treatment group was evaluated for changes over time, no 
significant differences were discovered. (* = p < 0.05) 
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Figure 36: Wild-Type/SPARC-null Hevin qRT-PCR 
 
A. 
B. 
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Figure 36 Legend: The same data presented in Figure 33 were also analyzed for 
differences between WT and SP-null mice. No significant differences were found 
between the two strains with regards to the expression of Hevin mRNA. 
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The levels of Hevin protein were also evaluated in both WT and SP-null mice 
exposed to asbestos (Figures 37 and 38). In WT mice, expression of Hevin protein was 
significantly increased at one week post LA exposure (Figure 37A). In SP-null mice, 
expression of Hevin was significantly increased at the one week time point for both 
amphibole exposure groups and also at the three month time point in CRO exposed 
animals (Figure 37B). When looking at changes over time, both WT and SP-null mice 
exposed to LA had a significant decrease in Hevin protein expression from one week to 
three months post-exposure (Figure 37A and 37B). CRO exposed SP-null mice have a 
significant decrease in Hevin protein levels from one week to one month, but then a 
significant increase from the one month to three month time points. Regardless there is 
still a significant decrease in Hevin from the one week to three month time points overall 
(Figure 37B). The level of Hevin protein in WT mice compared to SP-null mice was also 
examined (Figure 38). There were significant increases in Hevin protein in SP-null mice 
compared to WT mice exposed to CRO asbestos (Figure 38A). There was also a 
significant increase in Hevin protein levels at the one week time point in SP-null mice 
exposed to LA compared to their WT counterparts (Figure 38B). Furthermore, Hevin 
expression was significantly increased in response to LA at the one week time point in 
both WT and SP-null mouse lungs compared to PBS-treated controls.  
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Figure 37: Hevin Western Blot 
A. 
B. 
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Figure 37 Legend: Immunoblotting of Hevin protein from the lungs of C57Bl/6 WT or SP-
null mice exposed to PBS, CRO, or LA. Each blot was repeated three times.  Results from 
triplicate pools of RNA for each treatment group (n = 10 – 12 per group) were 
normalized to β-actin and are presented as the mean percent expression versus PBS ± 
SEM. At the one week time point, WT mice exposed to LA had significantly more Hevin 
protein expression and SP-null mice exposed to either amphibole had significantly higher 
levels of Hevin. CRO exposed SP-null mice had significantly increased levels of Hevin at 
three months after exposure. Over time, Hevin expression significantly decreased in LA 
exposed WT and SP-null mice from the one week to the three month time point. Also in 
SP-null mice, Hevin protein expression significantly decreased from the one week to one 
month time point, but then rebounded at the three month time point. (* = p < 0.05, ** 
= p < 0.01, *** = p < 0.001) 
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Figure 38: Wild-Type/SPARC-null Hevin Western Blot 
 
A. 
B. 
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Figure 38 Legend: The same data presented in Figure 35 were also analyzed for 
differences between WT and SP-null mice. CRO exposed SP-null mice expressed 
significantly more Hevin protein at both the one week and one month time points than 
their WT counterparts. LA exposed SP-null mice only had significantly more Hevin 
expression at the one week time point when compared to LA exposed WT mice. (* = p 
< 0.05, ** = p < 0.01, *** = p < 0.001) 
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Conclusion: 
 
 Though there were no apparent increases in Hevin mRNA in SP-null mice 
exposed to asbestos, there were significant increases in Hevin protein. This increase in 
Hevin protein appeared to occur mainly at one week after asbestos exposure and levels 
in SP-null mice were significantly higher than WT mice indicating that it may be 
compensating for SPARC in SP-null mice exposed to asbestos. As there were still 
significant decreases in hydroxyproline content in SP-null mice exposed to asbestos for 
one week compared to WT mice (Chapter 2, Figure 20), these results may indicate that 
if Hevin is compensating for a lack of SPARC, it is not doing so in the area of cell-matrix 
communication. But again, more research is needed to fully understand Hevin’s 
compensatory abilities.  
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